<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomedicines</journal-id><journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id><journal-id journal-id-type="publisher-id">biomedicines</journal-id><journal-title-group><journal-title>Biomedicines</journal-title></journal-title-group><issn pub-type="epub">2227-9059</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8869731</article-id><article-id pub-id-type="doi">10.3390/biomedicines10020212</article-id><article-id pub-id-type="publisher-id">biomedicines-10-00212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>KasQ an Epimerase Primes the Biosynthesis of Aminoglycoside Antibiotic Kasugamycin and KasF/H Acetyltransferases Inactivate Its Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rattinam</surname><given-names>Rajesh</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref><xref rid="af2-biomedicines-10-00212" ref-type="aff">2</xref><xref rid="af3-biomedicines-10-00212" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Basha</surname><given-names>R. Sidick</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yung-Lin</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhe-Chong</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5735-4606</contrib-id><name><surname>Hsu</surname><given-names>Ning-Shian</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Kuan-Hung</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zadeh</surname><given-names>Saeid Malek</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref><xref rid="af2-biomedicines-10-00212" ref-type="aff">2</xref><xref rid="af3-biomedicines-10-00212" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9530-3474</contrib-id><name><surname>Adhikari</surname><given-names>Kamal</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Jin-Ping</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9739-9761</contrib-id><name><surname>Li</surname><given-names>Tsung-Lin</given-names></name><xref rid="af1-biomedicines-10-00212" ref-type="aff">1</xref><xref rid="af2-biomedicines-10-00212" ref-type="aff">2</xref><xref rid="af4-biomedicines-10-00212" ref-type="aff">4</xref><xref rid="c1-biomedicines-10-00212" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Caputo</surname><given-names>Leonardo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Quintieri</surname><given-names>Laura</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Nicolotti</surname><given-names>Orazio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biomedicines-10-00212"><label>1</label>Genomics Research Center, Academia Sinica, Taipei 115, Taiwan; <email>rajeshbuibt@gmail.com</email> (R.R.); <email>sidickchem@gmail.com</email> (R.S.B.); <email>hcvns3@hotmail.com</email> (Y.-L.W.); <email>mournermind@gmail.com</email> (Z.-C.W.); <email>kevin320@gate.sinica.edu.tw</email> (N.-S.H.); <email>cardboy19821022@hotmail.com</email> (K.-H.L.); <email>saeid.malekzadeh@gmail.com</email> (S.M.Z.); <email>arsonkamal@yahoo.com</email> (K.A.); <email>jpl0815@gate.sinica.edu.tw</email> (J.-P.L.)</aff><aff id="af2-biomedicines-10-00212"><label>2</label>Chemical Biology and Molecular Biophysics Program, Taiwan International Graduate Program, Academia Sinica, Taipei 115, Taiwan</aff><aff id="af3-biomedicines-10-00212"><label>3</label>Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu 300, Taiwan</aff><aff id="af4-biomedicines-10-00212"><label>4</label>Biotechnology Center, National Chung Hsing University, Taichung City 402, Taiwan</aff><author-notes><corresp id="c1-biomedicines-10-00212"><label>*</label>Correspondence: <email>tlli@gate.sinica.edu.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2022</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>212</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Kasugamycin (KSM), an aminoglycoside antibiotic, is composed of three chemical moieties: D-<italic toggle="yes">chiro</italic>-inositol, kasugamine and glycine imine. Despite being discovered more than 50 years ago, the biosynthetic pathway of KSM remains an unresolved puzzle. Here we report a structural and functional analysis for an epimerase, KasQ, that primes KSM biosynthesis rather than the previously proposed KasF/H, which instead acts as an acetyltransferase, inactivating KSM. Our biochemical and biophysical analysis determined that KasQ converts UDP-GlcNAc to UDP-ManNAc as the initial step in the biosynthetic pathway. The isotope-feeding study further confirmed that <sup>13</sup>C, <sup>15</sup>N-glucosamine/UDP-GlcNH<sub>2</sub> rather than glucose/UDP-Glc serves as the direct precursor for the formation of KSM. Both KasF and KasH were proposed, respectively, converting UDP-GlcNH<sub>2</sub> and KSM to UDP-GlcNAc and 2-N&#x02019;-acetyl KSM. Experimentally, KasF is unable to do so; both KasF and KasH are instead KSM-modifying enzymes, while the latter is more specific and reactive than the former in terms of the extent of resistance. The information gained here lays the foundation for mapping out the complete KSM biosynthetic pathway.</p></abstract><kwd-group><kwd>kasugamycin</kwd><kwd>kasugamine</kwd><kwd>antibiotic biosynthesis</kwd><kwd>epimerase and acetyltransferase</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomedicines-10-00212"><title>1. Introduction</title><p>Kasugamycin (KSM), an aminoglycoside antibiotic produced by <italic toggle="yes">Streptomyces kasugaensis</italic>, was discovered in 1965. KSM is composed of three structurally distinct sub-components: a glycine imine, an unusual amino-sugar kasugamine and D-<italic toggle="yes">chiro</italic>-inositol (<xref rid="biomedicines-10-00212-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B1-biomedicines-10-00212" ref-type="bibr">1</xref>,<xref rid="B2-biomedicines-10-00212" ref-type="bibr">2</xref>]. It has long been known that KSM binds specially to the interface between E- and P-site of the 30S ribosomal subunit to control fungal and bacterial protein translation [<xref rid="B3-biomedicines-10-00212" ref-type="bibr">3</xref>]. KSM was used as an agricultural supplement to protect rice from fungus-derived diseases [<xref rid="B4-biomedicines-10-00212" ref-type="bibr">4</xref>]. Beyond that, a number of new findings revealed that KSM possesses several unexpected biological activities effectively countering some recalcitrant human diseases: (i) an in vitro and in vivo study showed that the combination of KSM with rifamycin is in a position to control <italic toggle="yes">Mycobacterium tuberculosis</italic>, [<xref rid="B5-biomedicines-10-00212" ref-type="bibr">5</xref>] (ii) KSM was recently shown to be capable of inhibiting herpes simplex virus-2 (HSV-2), [<xref rid="B6-biomedicines-10-00212" ref-type="bibr">6</xref>] and (iii) KSM has also been shown to have a promising activity against COVID-19 by inhibiting 3a-channel [<xref rid="B7-biomedicines-10-00212" ref-type="bibr">7</xref>] and chitinase 3-like-1 (CHI3L1) proteins [<xref rid="B8-biomedicines-10-00212" ref-type="bibr">8</xref>]. We were attracted by these new findings and thus eager to investigate the biosynthetic pathway of KSM in the hope of generating new and useful KSM analogs in the future.</p><p>The KSM biosynthetic pathway was proposed on the basis of the gene sequence similarity of each gene encoded in its biosynthetic gene cluster (BGC) [<xref rid="B9-biomedicines-10-00212" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-10-00212" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>]. However, the gene products responsible for the formation of UDP-N-acetyl-glucosamine (UDP-GlcNAc) and <italic toggle="yes">myo</italic>-inositol, the possible starting units for the formation of the kaugamine moiety, were still unclear (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S1</xref>). Five enzymes (KasF codes for an acetyltransferase, KasD codes for a NAD-dependent dehydratase, KasR codes for a PLP-dependent dehydratase, KasP codes for an oxidoreductase, and KasC codes for an aminotransferase) were proposed to act on UDP-GlcNAc in sequence to form the UDP-kasugamine precursor. Two downstream gene products&#x02014;KasN, a glycine oxidase, and KasQ, an epimerase&#x02014;may drive reactions toward UDP-kasugamine and UDP-carboxyformimidoyl-kasugamine sequentially. KasA, a glycosyltransferase, could couple UDP-carboxyformimidoyl-kasugamine and <italic toggle="yes">myo</italic>-inositol to form a KSM disaccharide precursor, then KasJ, an epimerase, could complete the synthetic pathway by epimerizing the equatorial C1-OH of <italic toggle="yes">myo</italic>-inositol to D-<italic toggle="yes">chiro</italic>-inositol (with an axial C1-OH) to afford KSM (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S1</xref>) [<xref rid="B9-biomedicines-10-00212" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-10-00212" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>]. KasH was reported as a self-resistance enzyme inactivating KSM by N2&#x02032;-acetylation [<xref rid="B12-biomedicines-10-00212" ref-type="bibr">12</xref>]. F. Kudo et al. recently came up with a new biosynthetic pathway for KSM [<xref rid="B13-biomedicines-10-00212" ref-type="bibr">13</xref>], whereas no intrinsic in vitro biochemical evidence was provided therein unequivocally delineating the actual roles of the enzymes designated in the biosynthesis of KSM. With the aim of determining the roles of these enzymes, our in silico analysis revealed that KasQ shares a high sequence similarity with many UDP-GlcNAc 2-epimerases, especially RffE (also referred to as WecB, 47% identity) and to SecA (44% identity). RffE converts UDP-GlcNAc to UDP-ManNAc in the early stage of enterobacterial common antigen (ECA) biosynthesis [<xref rid="B14-biomedicines-10-00212" ref-type="bibr">14</xref>]. Likewise, SecA performs the same reaction in the first step of the capsular polysaccharide (CPS) biosynthesis [<xref rid="B15-biomedicines-10-00212" ref-type="bibr">15</xref>]. L. Zhang et al. further examined the substrate specificity of SecA with a group of C2 N-acyl-modified UDP-GlcNAc and UDP-ManNAc derivatives, concluding that the C2 N-acyl group in the UDP-acylhexosamines is critical for molecular recognition [<xref rid="B16-biomedicines-10-00212" ref-type="bibr">16</xref>]. Of these facts, we speculated that KasQ should stand in the early stage of the biosynthetic pathway (converting UDP-GlcNAc <bold>1</bold> to UDP-ManNAc <bold>4</bold>; <xref rid="biomedicines-10-00212-f001" ref-type="fig">Figure 1</xref> and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S2</xref>) instead of the reported pathway where UDP-deoxy aminosugar is epimerized to UDP-kasugamine (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S1</xref>) [<xref rid="B9-biomedicines-10-00212" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-10-00212" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>]. This viewpoint, however, conflicted with the roles assigned for KasH and KasF; namely, they were proposed to prime and regulate the biosynthesis of KSM. We were thus prompted to resolve this long-standing issue by employing in vitro biochemical and biophysical analyses alongside in vivo isotope feeding assays, whereby we concluded that KasQ is the starter enzyme rather than KasF, and both KasF and KasH are self-resistant enzymes in the biosynthesis of KSM.</p></sec><sec id="sec2-biomedicines-10-00212"><title>2. Materials and Methods</title><sec id="sec2dot1-biomedicines-10-00212"><title>2.1. Cloning, Expression, and Purification</title><p>For the expression of KasQ, a gene was amplified from <italic toggle="yes">Streptomyces kasugaensis</italic> and cloned into expression vector pET28a+ to generate the protein with an N-terminal His<sub>6</sub> tag. The recombinant plasmid was transformed into <italic toggle="yes">Escherichia coli</italic> BL21 competent cells for protein overexpression. The transformed BL21 cells were used to inoculate LB medium (1000 mL) containing 1 mM kanamycin and the culture was grown at 37 &#x000b0;C. After reaching the OD at A600 nm of 0.6&#x02013;0.8, the culture was induced by the addition of 1 mM IPTG, followed by incubation at 16 &#x000b0;C overnight. Cells were harvested by centrifugation at 6000 rpm using a JLA8.1 rotor in a Beckman Coulter centrifuge for 25 min at 4 &#x000b0;C. The harvested (1000 mL) cells were resuspended in 20 mL of binding buffer (50 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol, and 10 mM imidazole). Resuspended cells were lysed using a sonicator (time, 4 min, pulse, 3 s on and 2 s off). The resulting lysate was centrifuged at 18,000 rpm (JA20.50 rotor, Beckman Coulter, Brea, CA, USA) for 30 min at 4 &#x000b0;C. The supernatant was added to a Ni-agarose affinity column equilibrated with binding buffer. The unbound proteins were washed off using varied imidazole concentrations (10 mM, 25 mM, and 50 mM). The protein was then eluted with elution buffer (50 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol, and 250 mM imidazole). The eluted protein samples were concentrated and injected into a Superdex S-200 column equilibrated with gel filtration buffer (50 mM HEPES pH 8.0, 100 mM NaCl). The peak fractions were collected and the purity of the KasQ protein was analyzed by 10% SDS-PAGE.</p><p>For the expression of KasH, a gene was amplified from <italic toggle="yes">Streptomyces kasugaensis</italic> and cloned into the expression vector pET28a+ to generate the protein with an N-terminal His<sub>6</sub> tag. The recombinant plasmid was transformed into <italic toggle="yes">E. coli</italic> BL21 competent cells and the protein was overexpressed. The purification steps of the above procedure were followed with the different gel filtration buffer (50 mM MOPS pH 7.5, 100 mM NaCl). The purity of the KasH protein was analyzed by 10% SDS-PAGE and confirmed by mass spectrometry (peptide mass fingerprinting).</p><p>For the expression of KasF, the gene was amplified from <italic toggle="yes">Streptomyces kasugaensis</italic> and cloned into the expression vector pET28a+ to generate the protein with an N-terminal His<sub>6</sub> tag. The recombinant plasmid was transformed into <italic toggle="yes">E. coli</italic> BL21 competent cells and the protein was overexpressed. The purification steps were followed by the above procedure with the different gel filtration buffer (50 mM HEPES pH 7.5, 200 mM NaCl). The purity of the KasF protein was analyzed by 10% SDS-PAGE and confirmed by mass spectrometry (peptide mass fingerprinting).</p></sec><sec id="sec2dot2-biomedicines-10-00212"><title>2.2. Crystallization and Data Collection</title><p>KasQ wild type (WT) and complex crystals were crystallized using the hanging drop vapor diffusion method at 20 &#x000b0;C. KasQ wild type (WT) protein was crystallized (7 mg mL<sup>&#x02212;1</sup>) in a buffer (50 mM HEPES pH 8.0, 100 mM NaCl) using a reservoir solution (0.2 M potassium/sodium tartrate, 0.1 M Bis-Tris propane pH 7.5 and 20% PEG 3350). KasQ&#x02013;WT crystals were formed after 7 days of incubation. The enzyme (10 mg mL<sup>&#x02212;1</sup>) was co-crystallized with 2 mM UDP or 2 mM UDP-Glc in the presence of 2 mM MgCl<sub>2</sub> with a reservoir solution containing 0.2 M lithium sulfate, 0.1 M Bis-Tris pH 5.5 and 25% PEG 3350 to obtain the KasQ&#x02013;UDP or KasQ&#x02013;UDP-Glc complex crystals. The complex crystals were formed after 15 days. Prior to the data collection, the crystals were transformed into the mother liquor containing 20% glycerol as a cryoprotectant and flash-frozen using liquid nitrogen. All the crystal data were collected in beamline 15A1 and 05A equipped with an ADSC Quantum-315 or MX300HE CCD detector (Rayonix, L.L.C., Evanston, IL, USA) at an operating temperature of 100K in National Synchrotron Radiation Research Center (NSRRC), Taiwan. The raw data were indexed and processed using the HKL2000 package (HKL Research, Inc., Charlottesville, VA, USA) [<xref rid="B17-biomedicines-10-00212" ref-type="bibr">17</xref>]. The KasQ&#x02013;WT crystal belongs to the C2 space group; the KasQ&#x02013;UDP and KasQ&#x02013;UDP-Glc complex crystals belong to the P1 space group. Detailed data collection statistics are shown in <xref rid="biomedicines-10-00212-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot3-biomedicines-10-00212"><title>2.3. Structure Determination and Refinement</title><p>The KasQ&#x02013;WT and its complex crystal structures were determined by molecular replacement (MR) with Phaser-MR from the CCP4 program suit [<xref rid="B18-biomedicines-10-00212" ref-type="bibr">18</xref>]. The <italic toggle="yes">E. coli</italic> UDP-GlcNAc epimerase (PDB entry 1vgv) was used as a search model to solve the initial phase [<xref rid="B19-biomedicines-10-00212" ref-type="bibr">19</xref>]. The protein structures were built and refined using REFMAC [<xref rid="B20-biomedicines-10-00212" ref-type="bibr">20</xref>], COOT [<xref rid="B21-biomedicines-10-00212" ref-type="bibr">21</xref>], and PHENIX [<xref rid="B22-biomedicines-10-00212" ref-type="bibr">22</xref>]. PyMOL as used to construct the protein structures and electron density maps [<xref rid="B23-biomedicines-10-00212" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot4-biomedicines-10-00212"><title>2.4. Site-Directed Mutagenesis</title><p>Site-directed mutagenesis was performed using QuikChange (Stratagene), following the manufacturer&#x02019;s protocol. The sequences of primers used in this study to create KasQ mutants are shown in <xref rid="biomedicines-10-00212-t002" ref-type="table">Table 2</xref>. The wild-type KasQ plasmid (BCRC12349) was used as the template for the single mutation. All mutations were confirmed by DNA sequencing. KasQ mutants were expressed and purified with the same protocol as used for the wild-type protein. </p></sec><sec id="sec2dot5-biomedicines-10-00212"><title>2.5. Isothermal Titration Calorimetry (ITC)</title><p>ITC analyses were carried out at 25 &#x000b0;C using an ITC200 microcalorimeter (MicroCal Inc., Northampton, MA, USA). The buffer solution (50 mM HEPES pH 8.0, 100 mM NaCl) was used to prepare protein and substrates for ITC analysis. Each titration contained 0.1 mM KasQ in the sample cell (250 &#x003bc;L), and 1 mM substrates was loaded into the syringe (40 &#x003bc;L). The titration experiment contains 18 injections (2 &#x003bc;L for a duration of 4 s) and each injection was separated by 120 s. The distilled water was filled in the reference cell throughout all titrations. The cell stirring speed was 1000 rpm. The collected raw data were processed in Origin 7.0 (provided by MicroCal) by a non-linear least square method to a single-site binding model. KasH ITC analyses were followed using the above procedure with a buffer solution of 50 mM MOPS pH 7.5, 100 mM NaCl.</p></sec><sec id="sec2dot6-biomedicines-10-00212"><title>2.6. Synthesis of 2-Acetamidoglucal (AAG)</title><p>AAG <bold>2</bold> was synthesized as shown in <xref rid="biomedicines-10-00212-sch001" ref-type="fig">Scheme 1</xref>. GlcNAc <bold>I</bold> reacts with acetyl chloride to yield glycosyl chloride <bold>II</bold>. Further reaction with isopropenyl acetate affords glucal <bold>III</bold>. Deacetylation of <bold>III</bold> using sodium methoxide provides <bold>2</bold>.</p><sec id="sec2dot6dot1-biomedicines-10-00212"><title>2.6.1. General Information</title><p><sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 600 spectrometer with tetramethylsilane as the internal reference. <sup>31</sup>P NMR was performed in Bruker Avance 500 AV NMR. Chemical shifts (&#x003b4; scale) were reported in parts per million (ppm). <sup>1</sup>H NMR spectra were reported in the order: multiplicity, number of protons, and coupling constant (J value) in hertz (Hz); signals were characterized as s (singlet), d (doublet), dd (doublet of doublet), and m (multiplet). Saturation transfer difference nuclear magnetic resonance (<sup>1</sup>H-STD NMR) was performed using a Bruker 600 MHz spectrometer, with KasQ and UDP-GlcNAc in a ratio of 1:100 recorded within 0&#x02013;5 min. A saturation time of 2s was employed. UDP-GlcNAc-relative STD (saturation transfer difference) effects were determined by (<italic toggle="yes">I</italic><sub>0</sub> &#x02013; <italic toggle="yes">I</italic><sub>sat</sub>)/<italic toggle="yes">I</italic><sub>0</sub>. (<italic toggle="yes">I</italic><sub>0</sub> &#x02013; <italic toggle="yes">I</italic><sub>sat</sub>) is the signal intensity in the STD NMR spectrum, whereas <italic toggle="yes">I</italic><sub>0</sub> is the signal intensity of the reference spectrum. Column chromatography was performed on silica gel (70&#x02013;230 mesh). TLC analysis was carried out on Merck Silica gel 60 F254 plates using MOSTAIN/<italic toggle="yes">p</italic>-anisaldehyde sugar staining. Compound <bold>2</bold> was synthesized by following a slight modification of the procedure described in the literature [<xref rid="B16-biomedicines-10-00212" ref-type="bibr">16</xref>].</p></sec><sec id="sec2dot6dot2-biomedicines-10-00212"><title>2.6.2. Procedure for the Synthesis of 2-Acetamidoglucal (AAG)</title><p>Acetyl chloride (6 mL), GluNAc <bold>I</bold> (2.00 g, 9.04 mmol) was added and stirred for up to 12 h. After that, CHCl<sub>3</sub> (20 mL) was added and the mixture was poured into ice-cold water. The organic layer was washed with an aqueous sodium bicarbonate solution (20 mL) and concentrated under reduced pressure. The crude residue was purified by flash column chromatography to obtain the pure glycosyl chloride <bold>II</bold> (1.65 g, 50%). <bold><sup>1</sup>H NMR</bold> (600 MHz, CDCl<sub>3</sub>) &#x003b4; 6.18 (d, <italic toggle="yes">J</italic> = 3.7 Hz, 1H), 5.88 (d, <italic toggle="yes">J</italic> = 8.7 Hz, 1H), 5.31 (dd, <italic toggle="yes">J</italic> = 10.8, 9.4 Hz, 1H), 5.20 (dd, <italic toggle="yes">J</italic> = 11.0, 8.6 Hz, 1H), 4.53 (ddd, <italic toggle="yes">J</italic> = 10.7, 8.8, 3.7 Hz, 1H), 4.27 (m, 2H), 4.13 (m, 1H), 2.09 (s, 3H), 2.04 (s, 6H), 1.98 (s, 3H). <bold><sup>13</sup>C NMR</bold> (150 MHz, CDCl<sub>3</sub>) &#x003b4; 171.7, 170.8, 170.3, 169.3, 93.8, 71.1, 70.3, 67.1, 61.3, 53.7, 23.3, 20.9, 20.7. The resulting chloride <bold>II</bold> (1.40 g, 3.83 mmol) was treated with isopropenyl acetate (28 mL) and <italic toggle="yes">p</italic>-TsOH (45 mg) and was refluxed at 130 &#x000b0;C for 24 h. Then, the mixture was concentrated under reduced pressure and the crude residue was purified by flash column chromatography to attain the pure glucal product <bold>III</bold> (0.682 g, 62%). <bold><sup>1</sup>H NMR</bold> (600 MHz, CDCl<sub>3</sub>) &#x003b4; 6.60 (s, 1H), 5.56 (d, <italic toggle="yes">J</italic> = 4.8 Hz, 1H), 5.25 (m, 1H), 4.51 (m, 1H), 4.47 (m, 1H), 4.19 (dd, <italic toggle="yes">J</italic> = 12.0, 3.0 Hz, 1H), 2.09 (s, 6H), 2.01 (s, 3H). <bold><sup>13</sup>C NMR</bold> (150 MHz, CDCl<sub>3</sub>) &#x003b4; 170.7, 170.0, 169.7, 148.0, 113.5, 74.9, 67.4, 67.1, 61.1, 20.9, 20.8. To a glucal <bold>III</bold> (0.600 g, 2.09 mmol), dry methanol (14 mL) was added and dissolved, then sodium methoxide was added (pH ~8.5) and the mixture was stirred for up to 2 h. The mixture was neutralized with Amberlite IR-120 (H+), filtered, and concentrated. The crude residue was purified by flash column chromatography and the pure solid product <bold>2</bold> (0.360 g, 85%) was obtained. <bold><sup>1</sup>H NMR</bold> (600 MHz, D<sub>2</sub>O) &#x003b4; 6.61 (s, 1H), 4.18 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 3.91 (m, 1H), 3.79 (d, <italic toggle="yes">J</italic> = 4.0 Hz, 2H), 3.69 (dd, <italic toggle="yes">J</italic> = 9.2, 6.8 Hz, 1H), 1.97 (s, 3H). <bold><sup>13</sup>C NMR</bold> (150 MHz, D<sub>2</sub>O) &#x003b4; 174.5, 141.7, 113.2, 78.5, 68.8, 68.4, 59.9, 21.9.</p></sec></sec><sec id="sec2dot7-biomedicines-10-00212"><title>2.7. Construction of pMKBAC08-KAS and pWZC07-PrpsJ-kasT</title><p>The <italic toggle="yes">E. coli-Streptomyces</italic> spp. shuttle BAC plasmid, pMKBAC08, was designed by amplifying the DNA segments containing the origin of transfer region (<italic toggle="yes">oriT</italic>) and the integrase and apramycin resistance gene, <italic toggle="yes">aacIII(IV)</italic>, within the primer set P325 and P326 from plasmid pGUSRolRPA3 [<xref rid="B24-biomedicines-10-00212" ref-type="bibr">24</xref>], and inserted into the BAC plasmid pBeloBAC11 (New England Biolabs, NEB).</p><p>pMKBAC08-KAS-Int, which carries an intact kasugamycin BGC, was constructed via sequentially cloning partial segments from the kasugamycin BGC into the pMKBAC08 plasmid as reported in previous studies [<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>]. Briefly, the DNA fragments containing the <italic toggle="yes">kasT</italic> gene, <italic toggle="yes">kasU-kasM</italic>, <italic toggle="yes">kasN-kasQ</italic>, <italic toggle="yes">kasR-kasB</italic>, and <italic toggle="yes">kasC-kasI</italic> were amplified with the primer sets P115/P116, P117/P118, P119/120, P121/P122m and P123/P124 (<xref rid="biomedicines-10-00212-t003" ref-type="table">Table 3</xref>). After digesting the amplicons by different restriction enzymes and individually introducing them into the pMKBAC08 vector using T4 DNA ligase, the BAC-containing kasugamycin BGC, pMKBAC08-KAS, was obtained.</p><p>The <italic toggle="yes">E. coli-Streptomyces</italic> spp. shuttle plasmid, pWZC07, was constructed by replacing the apramycin resistant gene, <italic toggle="yes">aacIII(IV)</italic>, in the plasmid pGUSRolRPA3 [<xref rid="B24-biomedicines-10-00212" ref-type="bibr">24</xref>] with the neomycin resistant gene, <italic toggle="yes">neo (Tn5)</italic>. To activate the expression of kasugamycin, the pWZC07-P<italic toggle="yes">rpsJ-kasT</italic> plasmid was constructed by cloning the <italic toggle="yes">rpsJ</italic> promoter fused with the <italic toggle="yes">kasT</italic> activator gene into the pWZC07 vector as reported previously [<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>].</p></sec><sec id="sec2dot8-biomedicines-10-00212"><title>2.8. In Vivo Isotope Incorporation Assay</title><p>For investigating the incorporation of the isotope-labeled compounds, <italic toggle="yes">Streptomyces lividans</italic> TK64 was introduced with pMKBAC08-KAS and pWZC07-P<italic toggle="yes">rpsJ-kasT</italic>. After being grown on an MS agar plate at 28 &#x000b0;C for 7 days [<xref rid="B25-biomedicines-10-00212" ref-type="bibr">25</xref>], the grown spores were inoculated into flasks (50 mL volume) containing 10 mL of KPMb medium (maltose monohydrate, 15 g/L; bacto-yeast extract, 4.0 g/L; phytone-peptone, 15 g/L; MgSO<sub>4</sub>&#x02219;7H<sub>2</sub>O, 0.5 g/L; KH<sub>2</sub>PO<sub>4</sub>, 1.0 g/L; and NaCl, 3.0 g/L.) and incubated at 28 &#x000b0;C for 5 days [<xref rid="B11-biomedicines-10-00212" ref-type="bibr">11</xref>]. After 24 h of incubation, isotope-labeled precursors (<sup>13</sup>C1-glucose; <sup>13</sup>C1-glucosamine; <sup>13</sup>C1-<sup>15</sup>N2-glucosamine; <sup>15</sup>N-glycine; <sup>15</sup>N-aspartic acid; and <sup>15</sup>N-glutamic acid) were prepared and added into the culture individually every 24 h until 72 h (17 mg/mL). After shaking for 96 h, the mycelium was removed from the culture broth and the filtrate was adjusted to pH 4.0 with oxalic acid. The treated samples were incubated at 70 &#x000b0;C for 20 min and then the supernatant was collected and analyzed after removing the debris by centrifuge. Supernatants were injected into the HPLC-TQ-MS and separated by the method described below.</p><list list-type="simple"><list-item><p>HPLC method A:</p></list-item></list><p>The supernatant was subjected to HPLC-TQ-MS with a Bridge BEH amide column (250 mm &#x000d7; 4.6 mm, 5 &#x000b5;m). The mobile phase was set up with a linear gradient, 30% H<sub>2</sub>O + 0.1 formic acid (FA) and 70% acetonitrile, at a flow rate of 1.0 mL min<sup>&#x02212;1</sup> over 30 min.</p></sec><sec id="sec2dot9-biomedicines-10-00212"><title>2.9. Disc Diffusion Assay</title><p>KSM susceptibility and production were confirmed by disc diffusion assay. An <italic toggle="yes">E. coli</italic> culture was grown at 37 &#x000b0;C overnight and spread on an LB agar plate (pH 7.0). About 5 &#x000b5;L of extracted samples from <italic toggle="yes">Streptomyces lividans</italic> TK64 (from days 2&#x02013;5) were loaded onto the paper disc. The disc was placed onto the surface of an LB agar plate and incubated at 37 &#x000b0;C overnight to visualize the zone of inhibition (ZOI).</p><p>For the KSM resistant assay, BL21 cells with/without the <italic toggle="yes">kasH</italic> or <italic toggle="yes">kasF</italic> gene were individually expressed and seeded on LB agar plates (pH 7.0). About 5 &#x000b5;L of different aminoglycoside antibiotics (amikacin, gentamicin, sisomicin, streptothricin-F, or tobramycin) were loaded onto each paper disc and placed on the surface of the LB plates. The plates were incubated 37 &#x000b0;C overnight to visualize the appearance of the zone of inhibition (ZOI). Note: this is a standard protocol for evaluating the effectiveness of common antibiotics, including aminoglycosides; there is no apparent impact concerning the structural integrity or biological deterioration of the selected aminoglycosides at pH 7.0 during the examining course.</p></sec><sec id="sec2dot10-biomedicines-10-00212"><title>2.10. HPLC Activity Assay</title><p>The epimerization reaction was carried out in a 100 &#x000b5;L reaction mixture containing 0.1 mg freshly purified KasQ, 1 mM UDP-GlcNAc, and 1 mM MgCl<sub>2</sub> in 25 mM Tris buffer, pH 8.0. The reactions were incubated at 37 &#x000b0;C for 12 h and quenched by adding equal volumes of chloroform. The precipitated protein was removed from the reaction mixture by centrifugation at 15,000 rpm for 20 min. For the screening of different NDP-sugar substrates, the enzymatic reactions were carried out in a 100 &#x000b5;L reaction mixture containing 0.1 mg KasQ, 1 mM NDP-Sugars (UDP-GalNAc, UDP-Glc, TDP-Glc, GDP-Glc, and UDP-Gal) in the presence of 1 mM MgCl<sub>2</sub> in 25 mM Tris buffer, pH 8.0. The reactions were incubated at 37 &#x000b0;C for 12 h and quenched by adding equal volumes of chloroform. The precipitated protein was removed from the reaction mixture by centrifugation at 15,000 rpm for 20 min. Supernatants were injected into the HPLC-LTQ-MS and separated by the method described below.</p><list list-type="simple"><list-item><p>HPLC method B:</p></list-item></list><p>The supernatant was subjected into HPLC-LTQ-MS with a Hypercarb Porous Graphitic Carbon Column (100 mm &#x000d7; 4.6 mm, 5 &#x000b5;m, Thermo Fisher Scientific, USA). The solvents used in the mobile phases were: solvent A: 50 mM ammonium formate; solvent B: 100% acetonitrile. A gradient started at 0&#x02013;5 min (solvent A: 95%; solvent B: 5%) and progressed to 18 min (solvent A: 60%; solvent B: 40%) and 24&#x02013;26 min (solvent A: 2%; solvent B: 98%) and ended at 28&#x02013;32 min (solvent A: 95%; solvent B: 5%) at a flow rate of 1.0 mL min<sup>&#x02212;1</sup>.</p><p>The acetylation reactions were carried out in a 100 &#x000b5;L reaction mixture containing 0.1 mg KasH or KasF, 1 mM KSM or UDP-GlcNH<sub>2</sub>, and 0.5 mM AcCoA in 25 mM Tris buffer, pH 8.0. The reactions were incubated 12 h at 37 &#x000b0;C and quenched by adding equal volumes of chloroform. Supernatants were injected into the HPLC-LTQ-MS and separated by the method described below.</p><list list-type="simple"><list-item><p>HPLC method C:</p></list-item></list><p>The supernatant was subjected into HPLC-LTQ-MS with a Phenomenex Prodigy C-18 column (250 mm &#x000d7; 4.6 mm, 5 &#x000b5;m). The solvents used in the mobile phases were: solvent A: H<sub>2</sub>O + 0.1% trifluoroacetic acid (TFA); solvent B: acetonitrile (ACN) + 0.1% TFA. A gradient started at 0&#x02013;5 min (solvent A: 98%; solvent B: 2%) and progressed to 18 min (solvent A: 60%; solvent B: 40%) and 24&#x02013;32 min (solvent A: 2%; solvent B: 98%) and ended at 35&#x02013;41 min (solvent A: 98%; solvent B: 2%) at a flow rate of 1.0 mL min<sup>&#x02212;1</sup>.</p></sec><sec id="sec2dot11-biomedicines-10-00212"><title>2.11. Thin Layer Chromatography (TLC) Analysis</title><p>About 1&#x02013;2 &#x000b5;L of AAG <bold>2</bold> and reaction mixture of KasQ with UDP-GlcNAc and MgCl<sub>2</sub> were spotted onto a TLC plate (Merck Silica gel 60 F254 plates). For aminoglucal detection, TLC was soaked with <italic toggle="yes">p</italic>-anisaldehyde stain solution and, upon gentle heating on a hot plate, the red color spot was visualized.</p></sec><sec id="sec2dot12-biomedicines-10-00212"><title>2.12. HPLC Kinetic Analysis</title><p>Kinetic analysis was performed in a 100 &#x000b5;L reaction mixture containing 0.1 mg freshly purified KasQ, six different concentrations of UDP-GlcNAc (0.25, 0. 50, 0.75, 1.00, 1.25, and 1.50 mM) and 1 mM MgCl<sub>2</sub> in 25 mM Tris buffer, pH 8.0. The reaction mixture was mixed by vortex and incubated at 37 &#x000b0;C. Reactions were stopped at six different time points (10, 30, 60, 120, 180, and 240 min) by adding equal volumes of chloroform. Precipitation was removed by centrifugation and analyzed by HPLC-LTQ-MS using HPLC method B as described above. Substrate (UDP-GlcNAc <bold>1</bold>) peaks were eluted at 10.69 min and products were (UDP-ManNAc <bold>4</bold>) eluted at 9.90 min, whereas the intermediates UDP <bold>3</bold> and AAG <bold>2</bold> were eluted at 9.51 min and 8.99 min, respectively. The Michaelis&#x02013;Menten curve of the KasQ activity was derived from the integrated peak area of each reaction.</p></sec><sec id="sec2dot13-biomedicines-10-00212"><title>2.13. NMR Activity Assay</title><p>Enzymatic reactions were performed in 25 mM Tris pH 8.0 with 1 mg freshly purified KasQ, 15 mM UDP-GlcNAc, and 5 mM MgCl<sub>2</sub> in a total reaction volume of 600 &#x000b5;L, incubated at 37 &#x000b0;C for 4 h. After incubation, the reaction was quenched by adding an equal volume of chloroform, and the supernatant was collected by centrifugation. The supernatant was filtered through a 3 kDa cut-off filter membrane (Millipore) and freeze-dried using a lyophilizer. The lyophilized product was dissolved in D<sub>2</sub>O (500 &#x000b5;L) and analyzed by NMR. For standards, a pure UDP-GlcNAc <bold>1</bold>, AAG <bold>2</bold>, and UDP <bold>3</bold> were dissolved in D<sub>2</sub>O (500 &#x000b5;L) and analyzed by NMR.</p><p>Similarly, time course NMR samples were prepared. The enzymatic reactions were stopped at six different time points (10 min, 30 min, 60 min, 120 min, 180 min, and 12 h) by adding an equal volume of chloroform, and supernatants were collected by centrifugation. The supernatants were filtered through a 3 kDa cut-off filter membrane (Millipore) and freeze-dried using a lyophilizer. The lyophilized product was dissolved in D<sub>2</sub>O (500 &#x000b5;L) and analyzed by <sup>1</sup>H and <sup>31</sup>P NMR spectroscopy.</p></sec><sec id="sec2dot14-biomedicines-10-00212"><title>2.14. Deuterium Incorporation Assay</title><p>Each enzymatic reaction was performed in a 100 &#x000b5;L reaction mixture containing 1 mM UDP-GlcNAc and 1 mM MgCl<sub>2</sub>, incubated with or without KasQ in D<sub>2</sub>O. Deuterium incorporation was stopped at nine different time points (0 min, 2 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, and 12 h) by adding equal volumes of chloroform. Supernatants were injected into the HPLC-LTQ-MS and separated by the method described below.</p><list list-type="simple"><list-item><p>HPLC method D:</p></list-item></list><p>The supernatant was subjected to HPLC-LTQ-MS with a Phenomenex Prodigy C-18 column (250 mm &#x000d7; 4.6 mm, 5 &#x000b5;m). The solvents used in the mobile phase were: solvent A: 50 mM ammonium formate; solvent B: 100% acetonitrile. A gradient started at 0&#x02013;6 min (solvent A: 92%; solvent B: 8%) and progressed to 7&#x02013;10 min (solvent A: 70&#x02013;50%; solvent B: 30&#x02013;50%) and 11&#x02013;21 min (solvent A: 98%; solvent B: 2%) at a flow rate 0.3 mL min<sup>&#x02212;1</sup>.</p></sec><sec id="sec2dot15-biomedicines-10-00212"><title>2.15. Computational Analysis</title><p>For sequence alignment, KasQ homologue protein sequences were retrieved from the National Center for Biotechnology Information (NCBI). Multiple sequence alignment was performed with Clustal Omega and the <italic toggle="yes">aln</italic> format file was uploaded into EsPript to construct the final image (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S21</xref>) [<xref rid="B26-biomedicines-10-00212" ref-type="bibr">26</xref>]. KasQ homolog selected active sites were uploaded to the Weblogo server to build the KasQ active site sequence logo [<xref rid="B27-biomedicines-10-00212" ref-type="bibr">27</xref>].</p></sec></sec><sec sec-type="results" id="sec3-biomedicines-10-00212"><title>3. Results and Discussion</title><sec id="sec3dot1-biomedicines-10-00212"><title>3.1. Biochemical Investigation of an Epimerase</title><p>In an attempt to validate the biochemical function of KasQ, N-terminally His-tagged KasQ was purified, which exists in solution as dimeric proteins (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S3</xref>). At first, potential substrates/intermediates UDP-GlcNAc <bold>1</bold>, 2-acetamidoglucal <bold>2</bold> (AAG), and UDP <bold>3</bold> were analyzed by HPLC-MS. Next, enzymatic reactions of KasQ incubated with UDP-GlcNAc and MgCl<sub>2</sub> were examined at various time points (<xref rid="biomedicines-10-00212-f002" ref-type="fig">Figure 2</xref>A,B and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S4</xref>). At 10 min, the expected product, UDP-ManNAc <bold>4</bold> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 605.15 [M-H]), appeared at the retention time of 9.90 min. On an elevated timeline, AAG <bold>2</bold> and UDP <bold>3</bold> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 402.20 [M-H]) emerged, respectively, at 8.99 and 9.51 min, and then increased over time (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S5</xref>). The generation of UDP-ManNAc <bold>4</bold> stagnated after 10 min and slightly increased at 12 h. The optimum temperature for KasQ epimerization activity was 37&#x02013;42 &#x000b0;C. (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S6</xref>). Next, the efficiency of the epimerase reaction was investigated. UDP-ManNAc formation was 6.8% at 10 min and marginally increased to 9.2% at 12 h. On the other hand, at 10 min AAG and UDP were formed at 0.2% and 1.1%, respectively. At 12 h, the conversion of AAG was 23.8% and that of UDP was 64.4%. UDP-ManNAc concentration was 2.6-fold lower than that of AAG and seven-fold lower than that of UDP, which indirectly suggested that the intermediates formed are thermodynamically stable, consistent with previous studies (<xref rid="biomedicines-10-00212-f002" ref-type="fig">Figure 2</xref>C and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S7</xref>) [<xref rid="B14-biomedicines-10-00212" ref-type="bibr">14</xref>].</p><p>The KasQ epimerase reaction was parallelly probed by NMR spectrometry. The reaction of UDP-GlcNAc in the presence of KasQ and MgCl<sub>2</sub> emanated the peak of a singlet at 6.60 ppm corresponding to an alkenyl proton of AAG and an appreciable amount of UDP-ManNAc was determined by its anomeric proton at 5.35 ppm. In contrast, a lesser number of UDP-GlcNAc anomeric protons at 5.41 ppm was observed (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S8</xref>). Extensive studies at various time intervals of the enzymatic reaction were executed (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>). AAG formed at 10 min and increased consistently with respect to time (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>B), whereas UDP-ManNAc formation from 10&#x02013;120 min remained almost the same and slightly increased at 12 h (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>C). The equilibrated existence of phosphorus in the epimerase reaction was tracked at various time periods by P<sup>31</sup> NMR spectrometry. At 10 min, UDP extrusion was observed with P<sub>&#x003b1;</sub> at &#x02212;8.7 ppm and P<sub>&#x003b2;</sub> at &#x02212;4.5 ppm, along with UDP-GlcNAc P<sub>&#x003b1;</sub> at &#x02212;11.7 ppm and P<sub>&#x003b2;</sub> at &#x02212;10.0 ppm. At a wider timespan, the UDP-GlcNAc peak was reduced and the UDP peak was intensified, whereas UDP-ManNAc P<sub>&#x003b1;</sub> and P<sub>&#x003b2;</sub> at &#x02212;12.8 and &#x02212;12.7 ppm moderately increased with respect to time (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>D). Enzymatic isotope labeling studies of UDP-GlcNAc were scantly documented [<xref rid="B14-biomedicines-10-00212" ref-type="bibr">14</xref>,<xref rid="B28-biomedicines-10-00212" ref-type="bibr">28</xref>]. To gain further insight into the KasQ epimerization reaction, a reversibility experiment was performed. UDP-GlcNAc with or without KasQ in the presence of MgCl<sub>2</sub> was incubated in D<sub>2</sub>O at different time intervals and the reaction mixtures were subjected to HPLC-MS analysis (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S9</xref>). No deuterium scrambling was observed when UDP-GlcNAc was incubated in D<sub>2</sub>O without KasQ up to 12 h (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 605.98 [M-H]) (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>E and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S9A</xref>). Moreover, in the presence of KasQ with UDP-GlcNAc and MgCl<sub>2</sub> in D<sub>2</sub>O, deuterium was labeled from 2 min to 12 h (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 606.96 [M-H]) (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>E and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S9B</xref>). To validate the position of the deuterium incorporation, NMR studies were performed (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>F,G). The C2 position of the UDP-GlcNAc was deuterated (97%) and appeared as a doublet at 5.36 ppm with minor traces of C2-deuterated UDP-ManNAc (&#x0003c;1%). Heavily incorporated deuterium at the C2 position of the UDP-GlcNAc clearly suggests that the abstraction of protons at the C2 position is highly reversible with the surrounding active-site residues of KasQ. It also postulates that first step of the reaction mechanism is highly reversible. A control experiment was performed to recognize the ability of thermodynamically stable AAG with UDP to generate UDP-ManNAc or UDP-GlcNAc. KasQ incubated with AAG and UDP in the presence of MgCl<sub>2</sub> was monitored by <sup>1</sup>H NMR (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S12</xref>). The absence of anomeric proton signals of UDP-ManNAc or UDP-GlcNAc concluded that the enzymatic reaction was ultimately futile. A similar finding was also noticed with SacA [<xref rid="B16-biomedicines-10-00212" ref-type="bibr">16</xref>]. An ITC experiment for AAG with KasQ showed unfavored binding in the medium (<xref rid="biomedicines-10-00212-t004" ref-type="table">Table 4</xref>). This implies that, thermodynamically, there is no binding affinity with KasQ for AAG. Enzyme binding interactions of UDP-GlcNAc were determined by saturation transfer difference (STD) NMR (<xref rid="biomedicines-10-00212-f003" ref-type="fig">Figure 3</xref>H). The proton binding epitope of UDP-GlcNAc with KasQ suggested that the ribose framework accumulated a major zone of interactions, whereas the GlcNAc and uridine moieties occupied a minor zone with KasQ. Both uridine H13 (the alkenyl group) and ribose H7 bind closely with KasQ, acquiring major STD effects. Moderate binding was attained on H8 and H9 of the ribose ring. GlcNAc H5, H14, and ribose H11 formed weak binding interactions with KasQ. Based on these binding studies of STD NMR and ITC analyses, we propose that the KasQ epimerase may proceed through a kinetically favorable or an enzyme-bound reaction mechanism. The proposed pathway for this epimerization reaction is from UDP-GlcNAc which undergoes an <italic toggle="yes">anti</italic>-elimination to generate AAG and UDP. Then, it undergoes subsequent <italic toggle="yes">syn</italic>-addition to afford an epimer UDP-ManNAc <bold>4</bold>. Overall, our biochemical investigations indicate that KasQ converts UDP-GlcNAc <bold>1</bold> to UDP-ManNAc <bold>4</bold> in a shorter reaction time, whereas in a prolonged reaction it releases a higher amount of AAG <bold>2</bold> and UDP <bold>3</bold>.</p></sec><sec id="sec3dot2-biomedicines-10-00212"><title>3.2. Biochemical Characterization of Acetyltransferases</title><p>The primary sequence analysis revealed that both KasF and KasH belong to enzymes of the acetyltransferase superfamily, while both share very low sequence identity (&#x0003c;10%) (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S13</xref>). Purified KasF forms monomers but KasH forms dimers in solution (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S3</xref>). The in vivo acetylation (resistance) activity of KasF and KasH versus KSM was evaluated with a disc diffusion assay (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S14</xref>). Individually, we introduced the pET28a+ plasmid carrying the <italic toggle="yes">kas</italic>F or <italic toggle="yes">kas</italic>H gene into the BL21 (DE3) <italic toggle="yes">E. coli</italic> cells. The <italic toggle="yes">E. coli</italic> cells (carrying the empty pET28a+ plasmid without the given acetyltransferase gene) were used as a control. We observed a clear zone of inhibition (ZOI) in the <italic toggle="yes">E. coli</italic> cells (not carrying the acetyltransferase gene) representing the cells&#x02019; inability to grow in the presence of KSM (the disc contained ~5 &#x003bc;L of 7.6 mg/mL of KSM). The growth of <italic toggle="yes">E. coli</italic> that carried the <italic toggle="yes">kas</italic>H gene was not affected in the presence KSM, whereas moderate growth of <italic toggle="yes">E. coli</italic> was observed in the cells carrying the <italic toggle="yes">kas</italic>F gene (<xref rid="biomedicines-10-00212-f004" ref-type="fig">Figure 4</xref>A and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S14</xref>). This phenomenon indicated that KasH serves as a resistance gene specific to KSM. Whether KasF is a resistance gene against other aminoglycoside antibiotics was further examined (<xref rid="biomedicines-10-00212-f004" ref-type="fig">Figure 4</xref>B,C and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S15</xref>). The activities of these two acetyltransferases against a number of commonly used aminoglycoside antibiotics (amikacin, gentamicin, kanamycin B, sisomicin, streptothricin-F, and tobramycin) were examined. The appearance of ZOI in all conditions strongly suggested that neither KasH nor KasF are active towards these aminoglycoside antibiotics (<xref rid="biomedicines-10-00212-f004" ref-type="fig">Figure 4</xref>B,C and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S15</xref>). Based on this in vivo assay we concluded that KasH serves as a self-resistance gene, while KasF partially acts as a self-resistance gene to KSM. To support this finding, an in vitro assay was performed. KasF or KasH were incubated with 1 mM KSM and 0.5 mM AcCoA at 37 &#x000b0;C for 12 h. KasH completely acetylated KSM (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 380.16 [M+H]) to produce 2&#x02032;N-acetyl-kasugamycin (Ac-KSM; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 422.38 [M+H]). Consistent with the in vivo analysis, KasF partially acetylated KSM (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 380.10 [M+H]) to form Ac-KSM (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 422.07 [M+H]) (<xref rid="biomedicines-10-00212-f004" ref-type="fig">Figure 4</xref>J&#x02013;M). As a result, KasH is the main self-resistance enzyme in the biosynthesis of KSM, but <italic toggle="yes">KasF</italic> may play a supportive role in the overall resistance system. Additionally, both KasF and KasH that are unable to acetylate the generally used aminoglycoside antibiotics (<xref rid="biomedicines-10-00212-f004" ref-type="fig">Figure 4</xref>D&#x02013;I) suggested that the two enzymes are a pair of resistance enzymes specific to KSM, the latter stronger than the former in terms of antimicrobial effectiveness. The specificity of KasF and KasH is due likely to their regioselectivity on KSM because it is an atypical aminoglycoside antibiotic, thereby incapable of acetylating other aminoglycosides. Isothermal titration calorimetry (ITC) was used to quantify the binding affinity of KasH versus CoA (<italic toggle="yes">K</italic><sub>d</sub> = 96.1 &#x000b5;M), AcCoA (<italic toggle="yes">K</italic><sub>d</sub> = 160.7 &#x000b5;M), and KSM (<italic toggle="yes">K</italic><sub>d</sub> = 56.1 &#x000b5;M). Among these binding affinity parameters, KasH and KSM concentrations are 2.9- and 1.7-fold higher than AcCoA and CoA, respectively (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S17 and Table S1</xref>). Although KasF is capable of partially acetylating KSM, it may not be a direct substrate. In the proposed biosynthetic pathway, KasF catalyzes the first step of reactions by converting UDP-GlcNH<sub>2</sub> to UDP-GlcNAc. To check this proposition, KasF was incubated with 1 mM UDP-GlcNH<sub>2</sub> and 0.5 mM AcCoA at 37 &#x000b0;C for 12 h. We could not observe the formation of UDP-GlcNAc, thus ruling out the possibility that KasF primes the KSM biosynthesis (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S18</xref>). The origin of UDP-GlcNH<sub>2</sub> or UDP-GlcNAc may be directly from the first metabolism, as they are fundamental metabolites. To test whether KasF carries out the deacetylation reaction in the KSM biosynthesis pathway (given UDP-GlcNAc the precursor, a deacetylase is required but not found in the KSM BGCs), KasF was incubated with 1 mM UDP-GlcNAc and 0.1 mM divalent ion (Zn<sup>2+</sup>). We found that neither KasF nor KasH was able to catalyze the deacetylation reaction (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S19</xref>).</p><p>A number of studies revealed that modified aminoglycoside antibiotics carried encouraging antimicrobial activity to inhibit some human pathogens [<xref rid="B29-biomedicines-10-00212" ref-type="bibr">29</xref>,<xref rid="B30-biomedicines-10-00212" ref-type="bibr">30</xref>,<xref rid="B31-biomedicines-10-00212" ref-type="bibr">31</xref>,<xref rid="B32-biomedicines-10-00212" ref-type="bibr">32</xref>]. For example, the enzymatically modified isepamicin (ISP), 6&#x02032;-N-acetylated ISP analogs, manifested stronger antimicrobial activity but less cytotoxicity than ISP against ISP-resistant Gram-negative pathogens [<xref rid="B33-biomedicines-10-00212" ref-type="bibr">33</xref>]. This fact prompted us to examine KasH for its ability to generate 2-N&#x02019;-acylated KSM analogs. KasH was examined in the presence of AcCoA, isovaleryl-CoA, &#x003b2;-hydroxybutyryl-CoA, acetoacetyl-CoA, and propionyl-CoA alongside KSM, whereby new 2-N&#x02019;-acyl substituted KSM analogs were generated (<xref rid="biomedicines-10-00212-f005" ref-type="fig">Figure 5</xref>). The binding affinity of KasH versus isovaleryl-CoA (<italic toggle="yes">K</italic><sub>d</sub> = 199.2 &#x000b5;M), acetoacetyl-CoA (<italic toggle="yes">K</italic><sub>d</sub> = 98.0 &#x000b5;M), and propionyl-CoA (<italic toggle="yes">K</italic><sub>d</sub> = 35.0 &#x000b5;M) was further determined (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S17 and Table S1</xref>), indicating that KasH has considerable substrate promiscuity when it comes to forming new analogs.</p></sec><sec id="sec3dot3-biomedicines-10-00212"><title>3.3. Crystal Structure of KasQ in Complex with UDP and UDP-Glc</title><p>To better understand the catalytic mechanism of KasQ, we solved crystal structures of KasQ for the wild type (WT) and its complexes with UDP or UDP-Glc in resolutions of 2.44 &#x000c5;, 2.58 &#x000c5;, and 2.09 &#x000c5;, respectively. Concerning the structure in complex with UDP-GlcNAc&#x02014;the structure that was most wanted&#x02014;it was not obtainable from all our co-crystallization conditions. Despite this, the structures, not least the one with UDP-Glc, are still in a position to provide a structural basis to help elucidate the mechanism of the epimerization reaction mediated by KasQ. <xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>A and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S20</xref>, respectively show the ribbon diagram of the tertiary structure and the topology diagram of the secondary structure of KasQ-WT. In consistence with homodimers in solution, an asymmetric unit contains two monomers colored in rainbow (N-terminal blue, C-terminal red) and gray. Superimposition of these two monomers with an RMSD of 0.86 &#x000c5; for 317 C&#x003b1; atoms indicated no significant conformational differences. In brief, each monomer consists of two domains (N-terminal and C-terminal domains), in which each subdomain is made of a typical sandwich (&#x003b1;&#x003b2;&#x003b1;) architecture of a Rossmann fold (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>A). Two fragments marked in dashed lines (residues 40&#x02013;45 in the N-terminal domain and residues 184&#x02013;190 in the C-terminal domain) are missing from the model due to lack of electron density, likely a consequence of structural disorder/flexibility in loop regions. The N-terminal domain is constituted by residues 1&#x02013;170 that fold into a central seven-strand &#x003b2;-sheet (&#x003b2;1&#x02013;&#x003b2;7) sandwiched by &#x003b1;-helices (&#x003b1;1&#x02013;&#x003b1;7) on each side along with a stand-alone &#x003b1;16 helix (residues 357&#x02013;370). The C-terminal domain is formed by residues 201&#x02013;359 composed of a central six-strand &#x003b2;-sheet (&#x003b2;8&#x02013;&#x003b2;13) sandwiched &#x003b1;-helices (&#x003b1;9&#x02013;&#x003b1;16) on each side. The N-terminal and C-terminal domains are connected by two helices, &#x003b1;7&#x02013;&#x003b1;8 (residues 173&#x02013;199). The cleft between these two domains provides the substrate binding pocket.</p><p>As revealed above, UDP or UDP-Glc is bound to its binding site at the interface of the two domains. The superimposition of KasQ&#x02013;UDP and KasQ&#x02013;UDP-Glc with an RMSD of 0.29 &#x000c5; for 332 C&#x003b1; atoms suggested no apparent conformational differences as a result of binding from different ligands (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>B). The electron density of UDP or UDP-Glc is well defined and consistent in the substrate binding site (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>C,D). The UDP binding site is highly conserved among all non-hydrolyzing UDP-GlcNAc 2-epimerases (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S21</xref>): the guanidino side chain of Arg12 and the backbone of Leu267 are in close contact with the uracil O2 atom, likely due to hydrogen bonding (3.1 &#x000c5; and 3.4 &#x000c5;, respectively). The backbone of Leu267 is also in a hydrogen-bonding distance to the O4 atom (3.1 &#x000c5;) and the N3 atom (2.7 &#x000c5;) of the uracil base. The two hydroxyl groups of the ribose moiety are associated with Glu292 (2.8 &#x000c5; and 2.6 &#x000c5;) by hydrogen bonds. His209 may play a role in stabilizing UDP by interacting with its &#x003b1;-phosphate (3.1 &#x000c5;) and &#x003b2;-phosphate (2.6 &#x000c5;). Ser286, Gly287, and Gly289 are three highly conserved residues for molecular recognition, in which Ser286 interacts with &#x003b1;/&#x003b2; phosphate (2.7 &#x000c5;/3.2 &#x000c5;, respectively), Gly287 is in contact with the O1/O2 atom of &#x003b2;-phosphate (3.3 &#x000c5;/3.1 &#x000c5;, respectively), and Gly289 is associated with the O1 atom of &#x003b2;-phosphate (2.9 &#x000c5;) (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>C).</p><p>In view of the KasQ&#x02013;UDP-Glc complex, the UDP portion is well defined as it is surrounded by an array of highly conserved residues, His209, Leu267, Ser286, Gly287, and Gly289. The hexose moiety is&#x000a0;held in place by a group of highly conserved residues for its recognition and epimerization, except for Arg12, which differs from the corresponding residues in other homologs pointing away from the uracil O2 atom (4.6 &#x000c5;); the guanidino group of Arg309, which is associated with Glu291 (2.9 &#x000c5;), is in close proximity to the C2 hydroxyl group (4.1 &#x000c5;), and the terminal carboxyl group of Asp97 is in close proximity to the C2 atom (3.8 &#x000c5;). These residues may act as a set of the interlinking acids/bases triggering the elimination/addition reaction for the epimerization of UDP-GlcNAc to UDP-ManNAc. The C3 hydroxyl group of the hexose moiety is also within hydrogen-bonding distances to both the guanidino group of Arg309 (2.7 &#x000c5;/2.9 &#x000c5;) and the carboxyl group of Glu119 (3.3 &#x000c5;). The C4 hydroxyl group is interacting with both Lys17 and Gln95 through hydrogen bonding (3.5 &#x000c5; and 3.1 &#x000c5;, respectively). The C6 hydroxyl group is likewise interacting with the carboxyl and amino groups of Asp97 through hydrogen bonding (2.5 &#x000c5; and 2.8 &#x000c5;, respectively). Importantly, the carboxyl group of Asp97 that is located on top of the sugar plane relative to the C2 atom (3.8 &#x000c5;) likely serves as the general base to deprotonate C2 in the first half of the reaction, yielding AAG and UDP; the Arg309/Glu291 dyad, on the other hand, acts as the general acid, likely protonating AAG to afford UDP-ManNAc, thus completing the epimerization reaction (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>D). Samuel et al. created five mutants of catalysis-related residues K15A, D95Q, E117Q, E131Q, and H213N to evaluate their biochemical importance [<xref rid="B34-biomedicines-10-00212" ref-type="bibr">34</xref>]: they observed that all the mutants can release the AAG intermediate. The activity of mutants D95Q and E131Q was 100-fold slower than that of the wild type. Although non-hydrolyzing UDP-GlcNAc 2-epimerases have been extensively studied, the catalytic residues that engage in the <italic toggle="yes">anti</italic>-elimination and <italic toggle="yes">syn</italic>-addition to form the product remain unclear. On the basis of the KasQ structural complexes, we highlighted the importance of two residues, Q95 and E308, which were mentioned less frequently in all UDP-GlcNAc 2-epimerases reported thus far (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S21</xref>). To confirm their importance, we prepared four mutants, Q95A, Q95E, E308A and E308Q, and performed biochemical assays by incubating them with UDP-GlcNAc and MgCl<sub>2</sub> at 37 &#x000b0;C for 12 h. For mutants E308A and E308Q, both HPLC and TLC analyses did not show the appearance of the intermediates, thereby confirming their importance in the catalysis (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S22</xref>). Moreover, given their special and geographic position relative to the AAG intermediate, we propose that Asp97 acts as the active site general base to trigger the elimination reaction, resulting in the formation of UDP and AAG. In contrast, both mutants Q95A and Q95E performed equally well, as did the wild type in terms of biochemical reactions, thus negating their direct participation in the epimerization reactions. To this end, obtaining the UDP-Glc or UDP bound complexes along with the mutagenesis studies allowed us to summarize the catalytic mechanism of KasQ: Asp97 may serve as the first base to abstract the C2 proton from GlcNAc, resulting in the formation of AAG and the neglect of UDP that is stabilized by nearby Arg210. Since the <italic toggle="yes">anti</italic>-elimination and <italic toggle="yes">syn</italic>-addition follow different electron-configuration courses, an oxocarbenium intermediate may be transiently present for buffering the transition state as well as helping change the reaction path. The positively charged oxocarbenium intermediate may be stabilized by the negatively charged UDP nearby [<xref rid="B35-biomedicines-10-00212" ref-type="bibr">35</xref>]. In the UDP-addition course, the Arg309/Glu291 dyad opposite to Asp97 may serve as the general acid to protonate AAG so that UDP-ManNAc is derived in a <italic toggle="yes">syn</italic>-addition manner, completing the epimerization reaction.</p></sec><sec id="sec3dot4-biomedicines-10-00212"><title>3.4. Structural Comparison</title><p>The primary sequence and tertial structural analysis revealed that KasQ is a homolog to many non-hydrolyzing UDP-GlcNAc 2-epimerases in bacteria (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S21</xref>), for example, 2-epimerase from <italic toggle="yes">E. coli</italic> (PDB entry 1vgv; 47% identity [<xref rid="B19-biomedicines-10-00212" ref-type="bibr">19</xref>]), <italic toggle="yes">Neisseria meningitidis</italic> (PDB entry 6vlc; 44% identity [<xref rid="B36-biomedicines-10-00212" ref-type="bibr">36</xref>]), <italic toggle="yes">Burkholderia vietnamiensis</italic> (PDB entry 5dld; 44% identity), and <italic toggle="yes">Bacillus subtilis</italic> (PDB entry 4fkz; 42% identity). Despite the fact that KasQ exists as dimers in solution as well as asymmetric units, only one UDP-Glc molecule is bound to one protomer of the dimer. The superimposition of the KasQ&#x02013;UDP-Glc complex with that from <italic toggle="yes">E. coli</italic> (PDB entry 1vgv) shows high structural similarity (RMSD of 1.0 &#x000c5; for 286 C&#x003b1;), UDP-glucose and UDP-ManNAc well overlapping each other in the active site, suggesting that both substrate-binding environments are comparable (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>A). In light of the residue sequence of the substrate/active site of KasQ, it is highly conserved except for Q95 when aligned against other homologs (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>B). Q95 was found interacting with the C4-OH of UDP-Glc (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>D) in contrast to the histidine (H) counterpart in homologous 2-epimerases, which is at a distance from C4-OH of 4.5 &#x000c5;. The close-up view out of these active sites suggests that there is adequate space for KasQ to accommodate UDP-GlcNAc or UDP-ManNAc (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S23</xref>). Residue R214 of that in <italic toggle="yes">E. coli</italic> is missing due to a lack of electron density (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>C), while both structures fit well (<italic toggle="yes">E. coli</italic> epimerase bound with UDP, PDB entry 1f6d; 47% identity [<xref rid="B37-biomedicines-10-00212" ref-type="bibr">37</xref>]) with an RMSD as low as 2.0 &#x000c5; for 298 C&#x003b1; (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>D). The UDP binding sites among all the selected epimerases are conserved (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>E) where residues SGG are highly conserved, likely to stabilize UDP by interacting with its &#x003b1;/&#x003b2;-phosphates through hydrogen bonds (<xref rid="biomedicines-10-00212-f007" ref-type="fig">Figure 7</xref>F).</p><p>A sodium ion was observed in coordination with the carbonyl backbone of N-terminal residues Leu25, Asp26, Asp28, and Phe31 (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S24</xref>). In the KasQ&#x02013;UDP complex, the carboxyl group of Glu32 makes an additional interaction with the Na<sup>+</sup> ion. Moreover, we found that the C-terminal residues Pro298, Ser250, and Ala352 of a KasQ homolog (PDB entry 1f6d) are associated with a Na<sup>+</sup> ion (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S24D</xref>). These metal-ion binding sites, however, are ~25 &#x000c5; away from the substrate binding region (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S24E</xref>), suggesting that they have little or no influences on the substrate-binding and enzymatic activity (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S24F</xref>).</p></sec><sec id="sec3dot5-biomedicines-10-00212"><title>3.5. KasQ Substrate Specificity</title><p>To investigate the substrate specificity, KasQ was assayed against an array of NDP-sugars. In brief, KasQ was incubated with NDP-sugars (UDP-GlcNAc, UDP-GalNAc, UDP-Glc, TDP-Glc, GDP-Glc, and UDP-Gal) in the presence of MgCl<sub>2</sub> at 37 &#x000b0;C for 12 h and then subjected to HPLC analysis. In comparison with standards (both retention time and molecular weight, <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>), we concluded that KasQ can only convert UDP-GlcNAc <bold>1</bold> to UDP-ManNAc <bold>4</bold>. The consumption of a considerable amount of UDP-GlcNAc and release of AAG <bold>2</bold> and UDP <bold>3</bold> in solution were observed in a 12 h reaction. The fact is that none of the other NDP-sugars can be hydrolyzed by KasQ, suggesting that UDP-GlcNAc is the only valid substrate (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S25</xref>). The kinetic parameters for KasQ in the presence of UDP-GlcNAc and MgCl<sub>2</sub> were determined: <italic toggle="yes">k</italic><sub>cat</sub> 1.33 s<sup>&#x02212;1</sup>, <italic toggle="yes">K</italic><sub>M</sub> 40.28 mM, and <italic toggle="yes">k</italic><sub>cat</sub>/<italic toggle="yes">K</italic><sub>M</sub> = 0.032 s<sup>&#x02212;1</sup>mM<sup>&#x02212;1</sup> (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S26 and Table S2</xref>). In addition, the dissociation constants (<italic toggle="yes">K</italic><sub>d</sub>) of KasQ versus nucleosides, (mono/di/tri) phosphates, NDP-sugars, and monosaccharides were examined using ITC, as summarized in <xref rid="biomedicines-10-00212-t004" ref-type="table">Table 4</xref> and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figures S27&#x02013;S29</xref>. Neither UDP-GlcNH<sub>2</sub> that was enzymatically synthesized using the published procedure [<xref rid="B38-biomedicines-10-00212" ref-type="bibr">38</xref>] nor AMP, ADP, ATP, GMP, GDP, or GTP shows detectable binding affinity with KasQ. We nevertheless observed some binding affinity in a micromolar range when KasQ was titrated with UMP (<italic toggle="yes">K</italic><sub>d</sub> = 123.9 &#x000b5;M), UDP (<italic toggle="yes">K</italic><sub>d</sub> = 32.2 &#x000b5;M), UTP (<italic toggle="yes">K</italic><sub>d</sub> = 71.4 &#x000b5;M), and TTP (<italic toggle="yes">K</italic><sub>d</sub> = 174.5 &#x000b5;M) (<xref rid="biomedicines-10-00212-t004" ref-type="table">Table 4</xref> and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S27</xref>). Of these, the binding affinity of UDP versus KasQ was shown to be 2&#x02013;5-fold higher than that of the others, suggesting that UDP-sugar is most likely the physiological substrate for KasQ. In contrast, UDP-Glc showed the highest binding affinity (<italic toggle="yes">K</italic><sub>d</sub> = 9.5 &#x000b5;M) in contrast to UDP-GlcNAc, which, for some reason, could not be determined (<xref rid="biomedicines-10-00212-t004" ref-type="table">Table 4</xref> and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S28</xref>). We speculated that divalent ions (Mg<sup>2+</sup>) may influence the binding but cannot conclude this from the ITC assay. Interestingly, both mutants Q95A and Q95E showed high binding affinity versus UDP-GlcNAc (<italic toggle="yes">K</italic><sub>d</sub> = 45.2 &#x000b5;M and <italic toggle="yes">K</italic><sub>d</sub> = 14.2 &#x000b5;M, respectively) comparable to that of WT versus UDP-Glc (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S30 and Table S3</xref>). In addition, we performed time course assays for KasQ in the presence of UDP-Glc and MgCl<sub>2</sub>, while we could not observe the formation of 2-hydroxyglucal and UDP-mannose, thereby concluding that UDP-Glc is not a substrate (<xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S31</xref>). Given these facts, we summarized that Q95 interacts with the C4 hydroxyl group of UDP-Glc (<xref rid="biomedicines-10-00212-f006" ref-type="fig">Figure 6</xref>D), while mutants Q95A and Q95E are not able to bind with UDP-Gal (C4-axial hydroxyl group). We propose that Q95 may play a critical role in the control of the reaction rate, directionality, and product release. Our mutagenic study may have shed new light on this subtle regulation in KSM biosynthesis while the actuality may depend on future detailed kinetic and biochemical/biophysical examinations.</p></sec><sec id="sec3dot6-biomedicines-10-00212"><title>3.6. In Vivo Isotope Incorporation Analysis</title><p>The origin of the main chemical components of KSM has previously been examined using isotopically labeled sugars, glycine, or ammonia. These results as a whole revealed that glucose or mannose is the precursor of kasugamine, that the D-inositol moiety is derived from <italic toggle="yes">myo</italic>-inositol, and that the glycine imine side chain comes directly from glycine [<xref rid="B39-biomedicines-10-00212" ref-type="bibr">39</xref>,<xref rid="B40-biomedicines-10-00212" ref-type="bibr">40</xref>,<xref rid="B41-biomedicines-10-00212" ref-type="bibr">41</xref>,<xref rid="B42-biomedicines-10-00212" ref-type="bibr">42</xref>,<xref rid="B43-biomedicines-10-00212" ref-type="bibr">43</xref>]. This information, however, is insufficient to shed light on the real roles of KasF, H, and Q in the biosynthesis of KSM. To address the insufficiency, we used <italic toggle="yes">Streptomyces lividans</italic> TK64 harboring pMKBAC08-KAS as a model system to produce KSM, for which the susceptibility of <italic toggle="yes">E. coli</italic> to KSM was gauged by disc diffusion assay to profile its production. The inhibition zone appeared in agar plates on the third day, suggesting that KSM had been produced to a considerable quantity by manifesting a significant inhibition zone against <italic toggle="yes">E. coli</italic> (<xref rid="biomedicines-10-00212-f008" ref-type="fig">Figure 8</xref>A and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S33</xref>). Samples collected from the culture medium were subjected to HPLC-TQ-MS (positive mode), whereby the molecular weight of KSM was determined with <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 380.1 [M+H] as a reference. To see if KSM directly derived from glucose or glucosamine, we fed three precursors, <sup>13</sup>C1-D-glucose, <sup>13</sup>C1-D-glucosamine, and <sup>13</sup>C1,<sup>15</sup>N2-D-glucosamine, to the culture of <italic toggle="yes">Streptomyces lividans</italic> TK64. We found that only <sup>13</sup>C1-D-glucose is partially incorporated into KSM, as shown by the isotopic profile of KSM with <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 380.1 [M+H], 381.2 [M+1+H], and 382.1 [M+2+H], in which the latter two displayed a ratio close to unit, likely as a result of D-glucose that serves as the precursor for both kasugamine and inositol in the KSM biosynthetic pathway (<xref rid="biomedicines-10-00212-f008" ref-type="fig">Figure 8</xref>B, <xref rid="app1-biomedicines-10-00212" ref-type="app">Figures S1 and S32</xref>). Given <sup>13</sup>C1-D-glucosamine, the isotopic profile is dissimilar to <sup>13</sup>C1-D-glucose, where it showed a dominant <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 381.2 [M+1+H] and a second dominant <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 382 [M+2+H] with a ratio close to 2 in contrast to the almost vanished native KSM (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 380.1 [M+H]), suggesting that glucosamine instead of glucose is the main or direct precursor of kasugamine and is readily convertible back to glucose at a high rate, an alternative source to <italic toggle="yes">myo</italic>-inositol (<xref rid="biomedicines-10-00212-f008" ref-type="fig">Figure 8</xref>B and <xref rid="app1-biomedicines-10-00212" ref-type="app">Figure S32</xref>). Given <sup>13</sup>C1,<sup>15</sup>N2-D-glucosamine, the isotopic profile showed the dominant <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at 382.2 [M+2+H] and 383 [M+3+H] with a ratio close to unit confirming the above reasoning. D-glucose is an indirect substrate, while glucosamine is the &#x0201c;direct&#x0201d; substrate in terms of utilization efficiency towards incorporation into KSM. On the other hand, given <sup>15</sup>N-glycine, the molecular weight of KSM increased by one mass unit (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 381.2 [M+1+H]), indicating that glycine is the key precursor for the carboxyformidoyl group at C4-NH<sub>2</sub> of KSM. Although UDP-N-Glc derivatives are the key precursors for KSM, the origin of the C4 amino group was parallelly investigated using <sup>15</sup>N-aspartic acid or <sup>15</sup>N-glutamic acid. An equal isotopic increment at M+H and M+1+H and a relatively minor extent of M+2+H for KSM were observed, suggesting that both <sup>15</sup>N-aspartic acid and <sup>15</sup>N-aspartic acid are the C4-NH<sub>2</sub> donor of KSM and a minor C2-NH<sub>2</sub> donor of glucosamine (<xref rid="biomedicines-10-00212-f008" ref-type="fig">Figure 8</xref>B,C). Based on our bioinformatics analysis, we put forward that KasC, the committed transaminase (28% similarity to PDB entry 5ghg, &#x003c9;-Transaminase), may transfer the amino group given by either of these two amine donors to the precursor of KSM [<xref rid="B44-biomedicines-10-00212" ref-type="bibr">44</xref>]; KasN, the committed glycine oxidase (42% similarity to fms14), may oxidatively add the glycine to the kasugamine precursor, forming carboxyformimidoyl-kasugamine [<xref rid="B45-biomedicines-10-00212" ref-type="bibr">45</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec4-biomedicines-10-00212"><title>4. Conclusions</title><p>In summary, KSM is produced by <italic toggle="yes">Streptomyces kasugaensis</italic>, isolated in 1965 [<xref rid="B2-biomedicines-10-00212" ref-type="bibr">2</xref>]. It has been widely used in agriculture because of good activities against a plethora of plant bacterial diseases, for example, to control rice bacterial grain and seedling rot [<xref rid="B4-biomedicines-10-00212" ref-type="bibr">4</xref>]. Beyond this, a number of new findings have highlighted that KSM is a promising drug lead, as it effectively counters some recalcitrant human diseases [<xref rid="B5-biomedicines-10-00212" ref-type="bibr">5</xref>,<xref rid="B6-biomedicines-10-00212" ref-type="bibr">6</xref>,<xref rid="B7-biomedicines-10-00212" ref-type="bibr">7</xref>,<xref rid="B8-biomedicines-10-00212" ref-type="bibr">8</xref>]. Unlike other aminoglycosides, KSM is composed of two unusual sugars, a D-<italic toggle="yes">chiro</italic>-inositol and a kasugamine with a glycine imine appendage. Whereas KSM has been discovered more than 50 years, its biosynthetic pathway remains still elusive due to lack of biochemical evidence. Based on the previous hypothesis, KasF was proposed as a starter enzyme involved in the formation of UDP-GlcNAc to initiate the biosynthesis of KSM, KasH as a self-resistance enzyme to regulate its biosynthesis, and KasQ as an enzyme standing in the middle of the pathway for the formation of kasugamine. In this study, we took advantage of in vitro biochemical and biophysical analyses alongside in vivo isotope feeding assays to solve these outstanding issues. First, we biochemically characterized the function of KasQ, which indeed is an epimerase converting UDP-GlcNAc to UDP-ManNAc, likely serving as the first step in the KSM biosynthesis. Mechanistically, we made use of NMR, stable isotope labelling, and synthetic AAG to ascertain that KasQ belongs to the un-hydrolyzing 2-epimerase protein family, in which the 2-epimerization reaction is carried out following the <italic toggle="yes">anti</italic>-elimination and <italic toggle="yes">syn</italic>-addition dual mechanisms. Structurally, we determined three crystal structures of KasQ for the wild type and its complex with UDP or UDP-Glc, thus allowing insights into the molecular recognition and catalytic mechanism at the molecular level. KasF was previously proposed as an enzyme that primes the biosynthesis of KSM; our in vivo and in vitro biochemical assays, however, ruled out this possibility. The fact is that UDP-GlcNH<sub>2</sub> cannot be converted to UDP-GlcNAc in the presence of KasF alongside AcCoA. KasF, nevertheless, shares the KSM-inactivation activity to some extent. By contrast, KasH is literally the aminoglycoside-modifying enzyme transferring the acetyl group from AcCoA specific to KSM to form 2-N&#x02019;-acetyl KSM. Finally, the isotope-feeding study confirmed that <sup>13</sup>C,<sup>15</sup>N-glucosamine/UDP-GlcNH<sub>2</sub> rather than glucose/UDP-Glc is the direct precursor in the formation of KSM. To this end, we have addressed several long-standing unresolved issues, which should be conducive toward mapping out the correct KSM biosynthetic pathway. The information garnered should also pave the way for developing novel KSM-based medicines using chemoenzymatic and synthetic biology approaches.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to acknowledge National Synchrotron Radiation Research Center (NSRRC), a national user facility supported by MOST of Taiwan, ROC. We thank NSRRC for beam time allocations at beam lines 13B, 05A, and 15A.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-biomedicines-10-00212"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/biomedicines10020212/s1">https://www.mdpi.com/article/10.3390/biomedicines10020212/s1</uri>, Figure S1: Previous biosynthetic proposals for kasugamycin (KSM), Figure S2: The proposed biosynthetic pathway of KSM from this study, Figure S3: Protein overexpression and purification for KasQ, KasF and KasH, Figure S4: The mass spectra (in m/z) of UDP-GlcNAc 1, UDP-ManNAc 4 and UDP 3 for the reactions carried out by KasQ in the presence of UDP-GlcNAc and MgCl<sub>2</sub>, Figure S5: The determination of the AAG 2 intermediate in time-course enzymatic reactions, Figure S6: Effects of different temperatures on the enzymatic activity of KasQ, Figure S7: The conversion rate of substrates to products, Figure S8: Trapping the intermediate and product formation by <sup>1</sup>H NMR spectroscopy, Figure S9: Determination of deuterated water incorporated into UDP-GlcNAc, Figure S10: The mass spectra of UDP-GlcNAc incubated with D<sub>2</sub>O at different time points, Figure S11: The mass spectra of KasQ incubated with UDP-GlcNAc and MgCl<sub>2</sub> in D<sub>2</sub>O at different time points, Figure S12: <sup>1</sup>H NMR spectra, Figure S13: The sequence alignment of KasH and KasF, Figure S14: Disc diffusion assay of KasF and KasH with or without KSM, Figure S15: Disc diffusion assay of KasF and KasH with some commonly used aminoglycoside antibiotics, Figure S16: The mass spectra of the substrates and products (in m/z) of the KasF, Figure S17: Isothermal Titration Calorimetry (ITC) analysis, Figure S18: Acetylation assay of KasF with UDP-GlcNH<sub>2</sub> and AcCoA, Figure S19: Deacetylation assay for KasH or KasF with UDP-GlcNAc and Zn<sup>2+</sup>, confirming that both enzymes are lack of the deacetylation activity, Figure S20: Topology diagram of the protein fold of the KasQ protomer, Figure S21: Sequence alignment of KasQ with different UDP-GlcNAc 2-epimerases, Figure S22: Biochemical assay of KasQ mutants E308A and E308Q, Figure S23: The active site and the binding pocket of KasQ, Figure S24: The metal-ion binding site of KasQ, Figure S25: Enzymatic reactions of KasQ with different NDP sugars, Figure S26: The kinetic curve of KasQ for the epimerization reactions, Figure S27: ITC analyses of KasQ with different nucleosides (mono/di/tri) phosphates, Figure S28: ITC analyses of KasQ with different NDP sugars, Figure S29: ITC analyses of KasQ with different monosaccharides, Figure S30: ITC analyses of KasQ mutants with different NDP sugars, Figure S31: <sup>1</sup>H NMR spectra of KasQ in time course reactions, Figure S32: Relative intensity of isotopes in mass spectra from different labeled sugar donors in order to probe the correct kasugamycin biosynthetic pathway, Figure S33: Disc diffusion test and mass spectrum of KSM, Figure S34: <sup>1</sup>H and <sup>13</sup>C NMR spectra, Figure S35: <sup>1</sup>H and <sup>13</sup>C NMR spectra, Figure S36: <sup>1</sup>H and <sup>13</sup>C NMR spectra, Table S1: Thermodynamic parameters of KasH for its binding affinity with testing ligands, Table S2: Kinetics of KasQ_WT in reaction with UDP-GlcNAc and MgCl<sub>2</sub>, Table S3: Thermodynamic parameters of KasQ mutants in the binding affinity assay. </p><supplementary-material id="biomedicines-10-00212-s001" position="float" content-type="local-data"><media xlink:href="biomedicines-10-00212-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, R.R. and T.-L.L.; methodology, R.R., R.S.B., Y.-L.W., Z.-C.W., N.-S.H., K.-H.L. and T.-L.L.; software, R.R., Y.-L.W. and T.-L.L.; validation, all authors.; formal analysis, all authors; investigation, R.R., R.S.B., Y.-L.W., Z.-C.W., N.-S.H., K.-H.L. and T.-L.L.; resources, T.-L.L.; data curation, R.R., R.S.B., Y.-L.W., Z.-C.W. and T.-L.L.; writing&#x02014;original draft preparation, R.R. and T.-L.L.; writing&#x02014;review and editing, all authors; visualization, R.R., R.S.B., Y.-L.W., Z.-C.W. and T.-L.L.; supervision, T.-L.L.; project administration, R.R. and T.-L.L.; funding acquisition, T.-L.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported by funds from the Ministry of Science and Technology (MOST), Taiwan (MOST-108-2113-M-001-021-MY3 and MOST 110-0210-01-22-02) and Academia Sinica (AS-KPQ-109-BioMed, 109-0210-01-18-02 and AS-IA-109-L06).</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All the data described in this article can be found in the text and <xref rid="app1-biomedicines-10-00212" ref-type="app">supplementary information</xref>; protein data bank (PDB) ID: 7VYY, 7VZA and 7VZ6.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biomedicines-10-00212"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikekawa</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
<name><surname>Iitaka</surname><given-names>Y.</given-names></name>
</person-group><article-title>The structure of kasugamycin hydrobromide by x-ray crystallographic analysis</article-title><source>J. Antibiot.</source><year>1966</year><volume>19</volume><fpage>49</fpage><lpage>50</lpage></element-citation></ref><ref id="B2-biomedicines-10-00212"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Suhara</surname><given-names>Y.</given-names></name>
<name><surname>Hashimoto</surname><given-names>T.</given-names></name>
<name><surname>Ikekawa</surname><given-names>T.</given-names></name>
</person-group><article-title>Kasugamycin, a new antibiotic</article-title><source>Antimicrob. Agents Chemother.</source><year>1965</year><volume>5</volume><fpage>753</fpage><lpage>757</lpage><?supplied-pmid 5883494?><pub-id pub-id-type="pmid">5883494</pub-id></element-citation></ref><ref id="B3-biomedicines-10-00212"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schuwirth</surname><given-names>B.S.</given-names></name>
<name><surname>Day</surname><given-names>J.M.</given-names></name>
<name><surname>Hau</surname><given-names>C.W.</given-names></name>
<name><surname>Janssen</surname><given-names>G.R.</given-names></name>
<name><surname>Dahlberg</surname><given-names>A.E.</given-names></name>
<name><surname>Cate</surname><given-names>J.H.</given-names></name>
<name><surname>Vila-Sanjurjo</surname><given-names>A.</given-names></name>
</person-group><article-title>Structural analysis of kasugamycin inhibition of translation</article-title><source>Nat. Struct. Mol. Biol.</source><year>2006</year><volume>13</volume><fpage>879</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/nsmb1150</pub-id><?supplied-pmid 16998486?><pub-id pub-id-type="pmid">16998486</pub-id></element-citation></ref><ref id="B4-biomedicines-10-00212"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishiyama</surname><given-names>T.</given-names></name>
<name><surname>Hara</surname><given-names>I.</given-names></name>
<name><surname>Matsuoka</surname><given-names>M.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Shimada</surname><given-names>S.</given-names></name>
<name><surname>Izawa</surname><given-names>R.</given-names></name>
<name><surname>Hashimoto</surname><given-names>T.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Okami</surname><given-names>Y.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Studies on the preventive effect of kasugamycin on rice blast</article-title><source>J. Antibiot.</source><year>1965</year><volume>18</volume><fpage>115</fpage><lpage>119</lpage></element-citation></ref><ref id="B5-biomedicines-10-00212"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaudhuri</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.X.</given-names></name>
<name><surname>Toosky</surname><given-names>M.N.</given-names></name>
<name><surname>Gardner</surname><given-names>M.</given-names></name>
<name><surname>Pan</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Y.Y.</given-names></name>
<name><surname>Kawaji</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Kasugamycin potentiates rifampicin and limits emergence of resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic> by specifically decreasing mycobacterial mistranslation</article-title><source>elife</source><year>2018</year><volume>7</volume><fpage>e36782</fpage><pub-id pub-id-type="doi">10.7554/eLife.36782</pub-id><?supplied-pmid 30152756?><pub-id pub-id-type="pmid">30152756</pub-id></element-citation></ref><ref id="B6-biomedicines-10-00212"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gopinath</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>M.V.</given-names></name>
<name><surname>Rakib</surname><given-names>T.</given-names></name>
<name><surname>Wong</surname><given-names>P.W.</given-names></name>
<name><surname>van Zandt</surname><given-names>M.</given-names></name>
<name><surname>Barry</surname><given-names>N.A.</given-names></name>
<name><surname>Kaisho</surname><given-names>T.</given-names></name>
<name><surname>Goodman</surname><given-names>A.L.</given-names></name>
<name><surname>Iwasaki</surname><given-names>A.</given-names></name>
</person-group><article-title>Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner</article-title><source>Nat. Microbiol.</source><year>2018</year><volume>3</volume><fpage>611</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0138-2</pub-id><pub-id pub-id-type="pmid">29632368</pub-id></element-citation></ref><ref id="B7-biomedicines-10-00212"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomar</surname><given-names>P.P.S.</given-names></name>
<name><surname>Krugliak</surname><given-names>M.</given-names></name>
<name><surname>Arkin</surname><given-names>I.T.</given-names></name>
</person-group><article-title>Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>532</elocation-id><pub-id pub-id-type="doi">10.3390/v13030532</pub-id><pub-id pub-id-type="pmid">33807095</pub-id></element-citation></ref><ref id="B8-biomedicines-10-00212"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamle</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>B.</given-names></name>
<name><surname>He</surname><given-names>C.H.</given-names></name>
<name><surname>Akosman</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>C.M.</given-names></name>
<name><surname>El-Deiry</surname><given-names>W.S.</given-names></name>
<name><surname>Huntington</surname><given-names>K.</given-names></name>
<name><surname>Liang</surname><given-names>O.</given-names></name>
<name><surname>Machan</surname><given-names>J.T.</given-names></name>
<etal/>
</person-group><article-title>Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><fpage>e148749</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.148749</pub-id><?supplied-pmid 34747367?><pub-id pub-id-type="pmid">34747367</pub-id></element-citation></ref><ref id="B9-biomedicines-10-00212"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flatt</surname><given-names>P.M.</given-names></name>
<name><surname>Mahmud</surname><given-names>T.</given-names></name>
</person-group><article-title>Biosynthesis of aminocyclitol-aminoglycoside antibiotics and related compounds</article-title><source>Nat. Prod. Rep.</source><year>2007</year><volume>24</volume><fpage>358</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1039/B603816F</pub-id><?supplied-pmid 17390001?><pub-id pub-id-type="pmid">17390001</pub-id></element-citation></ref><ref id="B10-biomedicines-10-00212"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikeno</surname><given-names>S.</given-names></name>
<name><surname>Aoki</surname><given-names>D.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Hori</surname><given-names>M.</given-names></name>
<name><surname>Tsuchiya</surname><given-names>K.S.</given-names></name>
</person-group><article-title>DNA sequencing and transcriptional analysis of the kasugamycin biosynthetic gene cluster from <italic toggle="yes">Streptomyces kasugaensis</italic> M338-M1</article-title><source>J. Antibiot.</source><year>2006</year><volume>59</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/ja.2006.4</pub-id></element-citation></ref><ref id="B11-biomedicines-10-00212"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasuga</surname><given-names>K.</given-names></name>
<name><surname>Sasaki</surname><given-names>A.</given-names></name>
<name><surname>Matsuo</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>C.</given-names></name>
<name><surname>Minato</surname><given-names>Y.</given-names></name>
<name><surname>Kuwahara</surname><given-names>N.</given-names></name>
<name><surname>Fujii</surname><given-names>C.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Agematu</surname><given-names>H.</given-names></name>
<name><surname>Tamura</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Heterologous production of kasugamycin, an aminoglycoside antibiotic from <italic toggle="yes">Streptomyces kasugaensis</italic>, in <italic toggle="yes">Streptomyces lividans</italic> and <italic toggle="yes">Rhodococcus erythropolis</italic> L-88 by constitutive expression of the biosynthetic gene cluster</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2017</year><volume>101</volume><fpage>4259</fpage><lpage>4268</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8189-5</pub-id><?supplied-pmid 28243709?><pub-id pub-id-type="pmid">28243709</pub-id></element-citation></ref><ref id="B12-biomedicines-10-00212"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikeno</surname><given-names>S.</given-names></name>
<name><surname>Tsuji</surname><given-names>T.</given-names></name>
<name><surname>Higashide</surname><given-names>K.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Hori</surname><given-names>M.</given-names></name>
</person-group><article-title>A 7.6 kb DNA region from <italic toggle="yes">Streptomyces kasugaensis</italic> M338-M1 includes some genes responsible for kasugamycin biosynthesis</article-title><source>J. Antibiot.</source><year>1998</year><volume>51</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.51.341</pub-id></element-citation></ref><ref id="B13-biomedicines-10-00212"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kudo</surname><given-names>F.</given-names></name>
</person-group><article-title>2.22&#x02014;Biosynthesis of Aminoglycoside Antibiotics</article-title><source>Comprehensive Natural Products III</source><person-group person-group-type="editor">
<name><surname>Liu</surname><given-names>H.-W.</given-names></name>
<name><surname>Begley</surname><given-names>T.P.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2020</year><fpage>588</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-409547-2.14619-0</pub-id></element-citation></ref><ref id="B14-biomedicines-10-00212"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>P.M.</given-names></name>
<name><surname>Sala</surname><given-names>R.F.</given-names></name>
<name><surname>Tanner</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Eliminations in the Reactions Catalyzed by UDP-N-Acetylglucosamine 2-Epimerase</article-title><source>J. Am. Chem. Soc.</source><year>1997</year><volume>119</volume><fpage>10269</fpage><lpage>10277</lpage><pub-id pub-id-type="doi">10.1021/ja971718q</pub-id></element-citation></ref><ref id="B15-biomedicines-10-00212"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swartley</surname><given-names>J.S.</given-names></name>
<name><surname>Liu</surname><given-names>L.J.</given-names></name>
<name><surname>Miller</surname><given-names>Y.K.</given-names></name>
<name><surname>Martin</surname><given-names>L.E.</given-names></name>
<name><surname>Edupuganti</surname><given-names>S.</given-names></name>
<name><surname>Stephens</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Characterization of the gene cassette required for biosynthesis of the (alpha1--&#x0003e;6)-linked N-acetyl-D-mannosamine-1-phosphate capsule of serogroup A Neisseria meningitidis</article-title><source>J. Bacteriol.</source><year>1998</year><volume>180</volume><fpage>1533</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1128/JB.180.6.1533-1539.1998</pub-id><pub-id pub-id-type="pmid">9515923</pub-id></element-citation></ref><ref id="B16-biomedicines-10-00212"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Muthana</surname><given-names>M.M.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>McArthur</surname><given-names>J.B.</given-names></name>
<name><surname>Qu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Characterizing non-hydrolyzing Neisseria meningitidis serogroup A UDP-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase using UDP-N-acetylmannosamine (UDP-ManNAc) and derivatives</article-title><source>Carbohydr. Res.</source><year>2016</year><volume>419</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.carres.2015.10.016</pub-id><pub-id pub-id-type="pmid">26598987</pub-id></element-citation></ref><ref id="B17-biomedicines-10-00212"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Otwinowski</surname><given-names>Z.</given-names></name>
<name><surname>Minor</surname><given-names>W.</given-names></name>
</person-group><article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title><source>Methods Enzymol.</source><year>1997</year><volume>276</volume><fpage>307</fpage><lpage>326</lpage></element-citation></ref><ref id="B18-biomedicines-10-00212"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCoy</surname><given-names>A.J.</given-names></name>
<name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name>
<name><surname>Adams</surname><given-names>P.D.</given-names></name>
<name><surname>Winn</surname><given-names>M.D.</given-names></name>
<name><surname>Storoni</surname><given-names>L.C.</given-names></name>
<name><surname>Read</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Phaser crystallographic software</article-title><source>J. Appl. Crystallogr.</source><year>2007</year><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><?supplied-pmid 19461840?><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="B19-biomedicines-10-00212"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Badger</surname><given-names>J.</given-names></name>
<name><surname>Sauder</surname><given-names>J.M.</given-names></name>
<name><surname>Adams</surname><given-names>J.M.</given-names></name>
<name><surname>Antonysamy</surname><given-names>S.</given-names></name>
<name><surname>Bain</surname><given-names>K.</given-names></name>
<name><surname>Bergseid</surname><given-names>M.G.</given-names></name>
<name><surname>Buchanan</surname><given-names>S.G.</given-names></name>
<name><surname>Buchanan</surname><given-names>M.D.</given-names></name>
<name><surname>Batiyenko</surname><given-names>Y.</given-names></name>
<name><surname>Christopher</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Structural analysis of a set of proteins resulting from a bacterial genomics project</article-title><source>Proteins</source><year>2005</year><volume>60</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1002/prot.20541</pub-id><?supplied-pmid 16021622?><pub-id pub-id-type="pmid">16021622</pub-id></element-citation></ref><ref id="B20-biomedicines-10-00212"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vagin</surname><given-names>A.A.</given-names></name>
<name><surname>Steiner</surname><given-names>R.A.</given-names></name>
<name><surname>Lebedev</surname><given-names>A.A.</given-names></name>
<name><surname>Potterton</surname><given-names>L.</given-names></name>
<name><surname>McNicholas</surname><given-names>S.</given-names></name>
<name><surname>Long</surname><given-names>F.</given-names></name>
<name><surname>Murshudov</surname><given-names>G.N.</given-names></name>
</person-group><article-title>REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use</article-title><source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><year>2004</year><volume>60</volume><fpage>2184</fpage><lpage>2195</lpage><pub-id pub-id-type="doi">10.1107/S0907444904023510</pub-id><?supplied-pmid 15572771?><pub-id pub-id-type="pmid">15572771</pub-id></element-citation></ref><ref id="B21-biomedicines-10-00212"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emsley</surname><given-names>P.</given-names></name>
<name><surname>Lohkamp</surname><given-names>B.</given-names></name>
<name><surname>Scott</surname><given-names>W.G.</given-names></name>
<name><surname>Cowtan</surname><given-names>K.</given-names></name>
</person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><year>2010</year><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><?supplied-pmid 20383002?><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="B22-biomedicines-10-00212"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afonine</surname><given-names>P.V.</given-names></name>
<name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name>
<name><surname>Echols</surname><given-names>N.</given-names></name>
<name><surname>Headd</surname><given-names>J.J.</given-names></name>
<name><surname>Moriarty</surname><given-names>N.W.</given-names></name>
<name><surname>Mustyakimov</surname><given-names>M.</given-names></name>
<name><surname>Terwilliger</surname><given-names>T.C.</given-names></name>
<name><surname>Urzhumtsev</surname><given-names>A.</given-names></name>
<name><surname>Zwart</surname><given-names>P.H.</given-names></name>
<name><surname>Adams</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Towards automated crystallographic structure refinement with phenix.refine</article-title><source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><year>2012</year><volume>68</volume><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id><pub-id pub-id-type="pmid">22505256</pub-id></element-citation></ref><ref id="B23-biomedicines-10-00212"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>DeLano</surname><given-names>W.L.</given-names></name>
</person-group><article-title>The PyMOL Molecular Graphics System</article-title><year>2002</year><comment>Available online: <ext-link xlink:href="http://www.pymol.org" ext-link-type="uri">http://www.pymol.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-11-18">(accessed on 18 November 2021)</date-in-citation></element-citation></ref><ref id="B24-biomedicines-10-00212"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horbal</surname><given-names>L.</given-names></name>
<name><surname>Fedorenko</surname><given-names>V.</given-names></name>
<name><surname>Luzhetskyy</surname><given-names>A.</given-names></name>
</person-group><article-title>Novel and tightly regulated resorcinol and cumate-inducible expression systems for Streptomyces and other actinobacteria</article-title><source>Appl. Microbiol. Biot.</source><year>2014</year><volume>98</volume><fpage>8641</fpage><lpage>8655</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-5918-x</pub-id><?supplied-pmid 25012786?><pub-id pub-id-type="pmid">25012786</pub-id></element-citation></ref><ref id="B25-biomedicines-10-00212"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kieser</surname><given-names>T.</given-names></name>
<name><surname>Hopwood</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Genetic Manipulation of Streptomyces&#x02014;Integrating Vectors and Gene Replacement</article-title><source>Methods Enzymol.</source><year>1991</year><volume>204</volume><fpage>430</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">1943784</pub-id></element-citation></ref><ref id="B26-biomedicines-10-00212"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robert</surname><given-names>X.</given-names></name>
<name><surname>Gouet</surname><given-names>P.</given-names></name>
</person-group><article-title>Deciphering key features in protein structures with the new ENDscript server</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>W320</fpage><lpage>W324</lpage><pub-id pub-id-type="doi">10.1093/nar/gku316</pub-id><?supplied-pmid 24753421?><pub-id pub-id-type="pmid">24753421</pub-id></element-citation></ref><ref id="B27-biomedicines-10-00212"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crooks</surname><given-names>G.E.</given-names></name>
<name><surname>Hon</surname><given-names>G.</given-names></name>
<name><surname>Chandonia</surname><given-names>J.M.</given-names></name>
<name><surname>Brenner</surname><given-names>S.E.</given-names></name>
</person-group><article-title>WebLogo: A sequence logo generator</article-title><source>Genome Res.</source><year>2004</year><volume>14</volume><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1101/gr.849004</pub-id><?supplied-pmid 15173120?><pub-id pub-id-type="pmid">15173120</pub-id></element-citation></ref><ref id="B28-biomedicines-10-00212"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salo</surname><given-names>W.L.</given-names></name>
</person-group><article-title>The incorporation of tritium from tritium-enriched water into UDP-N-Acetylglucosamine and UDP-N-Acetyl Mannosamine catalyzed by UDP-N-Acetylglucosamine 2-Epimerase from <italic toggle="yes">Escherichia coli</italic></article-title><source>Biochim. Biophys. Acta (BBA) Enzymol.</source><year>1976</year><volume>452</volume><fpage>625</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/0005-2744(76)90216-3</pub-id></element-citation></ref><ref id="B29-biomedicines-10-00212"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bellucci</surname><given-names>M.C.</given-names></name>
<name><surname>Volonterio</surname><given-names>A.</given-names></name>
</person-group><article-title>Aminoglycosides: From Antibiotics to Building Blocks for the Synthesis and Development of Gene Delivery Vehicles</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>504</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9080504</pub-id><?supplied-pmid 32796727?><pub-id pub-id-type="pmid">32796727</pub-id></element-citation></ref><ref id="B30-biomedicines-10-00212"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Litovchick</surname><given-names>A.</given-names></name>
<name><surname>Lapidot</surname><given-names>A.</given-names></name>
<name><surname>Eisenstein</surname><given-names>M.</given-names></name>
<name><surname>Kalinkovich</surname><given-names>A.</given-names></name>
<name><surname>Borkow</surname><given-names>G.</given-names></name>
</person-group><article-title>Neomycin B&#x02212;Arginine Conjugate, a Novel HIV-1 Tat Antagonist:&#x02009; Synthesis and Anti-HIV Activities</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>15612</fpage><lpage>15623</lpage><pub-id pub-id-type="doi">10.1021/bi0108655</pub-id><pub-id pub-id-type="pmid">11747436</pub-id></element-citation></ref><ref id="B31-biomedicines-10-00212"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llewellyn</surname><given-names>N.M.</given-names></name>
<name><surname>Spencer</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Chemoenzymatic acylation of aminoglycoside antibiotics</article-title><source>Chem. Commun.</source><year>2008</year><volume>32</volume><fpage>3786</fpage><lpage>3788</lpage><pub-id pub-id-type="doi">10.1039/b802248h</pub-id><?supplied-pmid 18685777?><pub-id pub-id-type="pmid">18685777</pub-id></element-citation></ref><ref id="B32-biomedicines-10-00212"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thamban Chandrika</surname><given-names>N.</given-names></name>
<name><surname>Garneau-Tsodikova</surname><given-names>S.</given-names></name>
</person-group><article-title>Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities</article-title><source>Chem. Soc. Rev.</source><year>2018</year><volume>47</volume><fpage>1189</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1039/C7CS00407A</pub-id><pub-id pub-id-type="pmid">29296992</pub-id></element-citation></ref><ref id="B33-biomedicines-10-00212"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ban</surname><given-names>Y.H.</given-names></name>
<name><surname>Song</surname><given-names>M.C.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Wi</surname><given-names>J.B.</given-names></name>
<name><surname>Park</surname><given-names>J.W.</given-names></name>
<name><surname>Lee</surname><given-names>D.G.</given-names></name>
<name><surname>Yoon</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>Development of 6&#x02032;-N-Acylated Isepamicin Analogs with Improved Antibacterial Activity Against Isepamicin-Resistant Pathogens</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.3390/biom10060893</pub-id><?supplied-pmid 32545254?><pub-id pub-id-type="pmid">32545254</pub-id></element-citation></ref><ref id="B34-biomedicines-10-00212"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samuel</surname><given-names>J.</given-names></name>
<name><surname>Tanner</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Active site mutants of the &#x0201c;non-hydrolyzing&#x0201d; UDP-N-acetylglucosamine 2-epimerase from <italic toggle="yes">Escherichia coli</italic></article-title><source>Biochim. Biophys. Acta</source><year>2004</year><volume>1700</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2004.03.017</pub-id><?supplied-pmid 15210128?><pub-id pub-id-type="pmid">15210128</pub-id></element-citation></ref><ref id="B35-biomedicines-10-00212"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitworth</surname><given-names>G.E.</given-names></name>
<name><surname>Macauley</surname><given-names>M.S.</given-names></name>
<name><surname>Stubbs</surname><given-names>K.A.</given-names></name>
<name><surname>Dennis</surname><given-names>R.J.</given-names></name>
<name><surname>Taylor</surname><given-names>E.J.</given-names></name>
<name><surname>Davies</surname><given-names>G.J.</given-names></name>
<name><surname>Greig</surname><given-names>I.R.</given-names></name>
<name><surname>Vocadlo</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: Mechanistic and structural insights into inhibitor selectivity and transition state poise</article-title><source>J. Am. Chem. Soc.</source><year>2007</year><volume>129</volume><fpage>635</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1021/ja065697o</pub-id><pub-id pub-id-type="pmid">17227027</pub-id></element-citation></ref><ref id="B36-biomedicines-10-00212"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurlburt</surname><given-names>N.K.</given-names></name>
<name><surname>Guan</surname><given-names>J.</given-names></name>
<name><surname>Ong</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Fisher</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Structural characterization of a nonhydrolyzing UDP-GlcNAc 2-epimerase from Neisseria meningitidis serogroup A</article-title><source>Acta Crystallogr. Sect. F Struct. Biol. Commun.</source><year>2020</year><volume>76</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1107/S2053230X20013680</pub-id><?supplied-pmid 33135674?><pub-id pub-id-type="pmid">33135674</pub-id></element-citation></ref><ref id="B37-biomedicines-10-00212"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>R.E.</given-names></name>
<name><surname>Mosimann</surname><given-names>S.C.</given-names></name>
<name><surname>Tanner</surname><given-names>M.E.</given-names></name>
<name><surname>Strynadka</surname><given-names>N.C.</given-names></name>
</person-group><article-title>The structure of UDP-N-acetylglucosamine 2-epimerase reveals homology to phosphoglycosyl transferases</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>14993</fpage><lpage>15001</lpage><pub-id pub-id-type="doi">10.1021/bi001627x</pub-id><pub-id pub-id-type="pmid">11106477</pub-id></element-citation></ref><ref id="B38-biomedicines-10-00212"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C.M.</given-names></name>
<name><surname>Lyu</surname><given-names>S.Y.</given-names></name>
<name><surname>Lin</surname><given-names>K.H.</given-names></name>
<name><surname>Chen</surname><given-names>C.L.</given-names></name>
<name><surname>Chen</surname><given-names>M.H.</given-names></name>
<name><surname>Shih</surname><given-names>H.W.</given-names></name>
<name><surname>Hsu</surname><given-names>N.S.</given-names></name>
<name><surname>Lo</surname><given-names>I.W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.L.</given-names></name>
<name><surname>Li</surname><given-names>Y.S.</given-names></name>
<etal/>
</person-group><article-title>Teicoplanin Reprogrammed with the N-Acyl-Glucosamine Pharmacophore at the Penultimate Residue of Aglycone Acquires Broad-Spectrum Antimicrobial Activities Effectively Killing Gram-Positive and -Negative Pathogens</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>430</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00317</pub-id><pub-id pub-id-type="pmid">30599088</pub-id></element-citation></ref><ref id="B39-biomedicines-10-00212"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukagawa</surname><given-names>Y.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Studies on biosynthesis of kasugamycin. I. Biosynthesis of kasugamycin and the kasugamine moiety</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.50</pub-id></element-citation></ref><ref id="B40-biomedicines-10-00212"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukagawa</surname><given-names>Y.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Biosynthesis of kasugamycin. II. Biosynthesis of the two-carbon-side chain of kasugamycin</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.182</pub-id></element-citation></ref><ref id="B41-biomedicines-10-00212"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukagawa</surname><given-names>Y.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Studies on biosynthesis of kasugamycin. 3. Biosynthesis of the d-inositol moiety</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.185</pub-id><?supplied-pmid 5673676?><pub-id pub-id-type="pmid">5673676</pub-id></element-citation></ref><ref id="B42-biomedicines-10-00212"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Fukagawa</surname><given-names>Y.</given-names></name>
<name><surname>Homma</surname><given-names>I.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Studies on biosynthesis of kasugamycin. VI. Some relationships between the incorporation of 14C-compounds and the production of kasugamycin</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.413</pub-id><?supplied-pmid 5723084?><pub-id pub-id-type="pmid">5723084</pub-id></element-citation></ref><ref id="B43-biomedicines-10-00212"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukagawa</surname><given-names>Y.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Homma</surname><given-names>I.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Umezawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Studies on biosynthesis of kasugamycin. V. Biosynthesis of the amidine group</article-title><source>J. Antibiot.</source><year>1968</year><volume>21</volume><fpage>410</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.21.410</pub-id><?supplied-pmid 5723083?><pub-id pub-id-type="pmid">5723083</pub-id></element-citation></ref><ref id="B44-biomedicines-10-00212"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>S.-W.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Cho</surname><given-names>H.-S.</given-names></name>
<name><surname>Shin</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Active Site Engineering of &#x003c9;-Transaminase Guided by Docking Orientation Analysis and Virtual Activity Screening</article-title><source>ACS Catal.</source><year>2017</year><volume>7</volume><fpage>3752</fpage><lpage>3762</lpage><pub-id pub-id-type="doi">10.1021/acscatal.6b03242</pub-id></element-citation></ref><ref id="B45-biomedicines-10-00212"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dairi</surname><given-names>T.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>K.</given-names></name>
<name><surname>Hasegawa</surname><given-names>M.</given-names></name>
</person-group><article-title>N-formimidoyl fortimicin A synthase, a unique oxidase involved in fortimicin A biosynthesis: Purification, characterization and gene cloning</article-title><source>Mol. Gen. Genet. MGG</source><year>1992</year><volume>236</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/BF00279642</pub-id><?supplied-pmid 1494350?><pub-id pub-id-type="pmid">1494350</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="biomedicines-10-00212-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>) The biosynthetic gene cluster (BGC) sequenced and identified from <italic toggle="yes">Streptomyces kasugaensis</italic>. (<bold>B</bold>) The proposed biosynthetic pathway of KSM based on the results revealed in this study. KasF is unable to acetylate UDP-GlcNH<sub>2</sub> to UDP-GlcNAc. KasQ initiates the KSM biosynthesis by converting UDP-GlcNAc <bold>1</bold> to UDPManNAc <bold>4</bold> through AAG <bold>2</bold> and UDP <bold>3</bold> intermediates. KasH acts as a self-resistance enzyme to acetylate kasugamycin (KSM) to 2-N&#x02019;-acetyl kasugamycin (Ac-KSM).</p></caption><graphic xlink:href="biomedicines-10-00212-g001" position="float"/></fig><fig position="float" id="biomedicines-10-00212-sch001"><object-id pub-id-type="pii">biomedicines-10-00212-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>The synthetic steps for AAG <bold>2</bold>.</p></caption><graphic xlink:href="biomedicines-10-00212-sch001" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f002"><label>Figure 2</label><caption><p>Biochemical investigation of KasQ by HPLC-LTQ-MS. (<bold>A</bold>) Time course assay for the KasQ-mediated reaction in the presence of UDP-GlcNAc. The assay scheme is shown at the top: <bold>1</bold>. UDP-GlcNAc, <bold>2</bold>. AAG, <bold>3</bold>. UDP, and <bold>4</bold>. UDP-ManNAc. (<bold>B</bold>) The <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> of UDP-GlcNAc, UDP-ManNAc, and UDP for the reaction carried out by KasQ in the presence of UDP-GlcNAc and MgCl<sub>2</sub> for 180 min. (<bold>C</bold>) The conversion rate of UDP-GlcNAc (orange) to UDP-ManNAc (brown), UDP (pink), and AAG (cyan) over 12 h time course.</p></caption><graphic xlink:href="biomedicines-10-00212-g002" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f003"><label>Figure 3</label><caption><p>Biochemical investigation of KasQ by NMR and mass spectrometry. (<bold>A</bold>) Scheme of the KasQ-mediated epimerization reaction. Proton and phosphorous labels are shown in structural formulas. (<bold>B</bold>) The <sup>1</sup>H NMR stack plot of AAG evolution. (<bold>C</bold>) Time course <sup>1</sup>H NMR spectra during UDP-ManNAc formation. (<bold>D</bold>) The <sup>31</sup>P NMR stack plot of varied time intervals. (<bold>E</bold>) The deuterium incorporation assay with or without KasQ was incubated with UDP-GlcNAc and MgCl<sub>2</sub> in D<sub>2</sub>O. (<bold>F</bold>,<bold>G</bold>) Reversibility experiment. The pink circle denotes anomeric protons of UDP-GlcNAc; red and black asterisks are the C2 deuterated UDP-GlcNAc and UDP-ManNAc anomeric protons. (<bold>H</bold>) <sup>1</sup>H-STD NMR analysis of UDP-GlcNAc in the presence of KasQ and the relative STD effects are shown in appropriate colors. The highest intensity of the STD signal signifies 100%, according to which the other signals were respectively calculated.</p></caption><graphic xlink:href="biomedicines-10-00212-g003" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f004"><label>Figure 4</label><caption><p>Biochemical characterization of acetyltransferases KasF and KasH. (<bold>A</bold>) Disc diffusion assay with or without KSM. The <italic toggle="yes">E. coli</italic> BL21 (DE3) strain was used as a control. (<bold>B</bold>,<bold>C</bold>) The in vivo resistance activity of KasF and KasH was assayed against amikacin, gentamicin, sisomicin, streptothricin-F, and tobramycin. (<bold>D</bold>&#x02013;<bold>I</bold>) The acetylation reactions of KasF and KasH were examined in the presence of AcCoA and different aminoglycoside antibiotics, (<bold>D</bold>) amikacin, (<bold>E</bold>) gentamicin, (<bold>F</bold>) kanamycin B, (<bold>G</bold>) sisomicin, (<bold>H</bold>) streptothricin-F, and (<bold>I</bold>) tobramycin. The EICs of (i) the antibiotic alone, (ii) KasF with the selected antibiotic and AcCoA, (iii) KasH with the selected antibiotic and AcCoA are displayed. (<bold>J</bold>,<bold>K</bold>) The acetylation reactions of KasF and KasH were examined in the presence of KSM and AcCoA, indicating that both KasF and KasH are specific to KSM. (<bold>L</bold>,<bold>M</bold>) MS spectra for the substrates and products (in <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>) of the KasF- and KasH-mediated reactions.</p></caption><graphic xlink:href="biomedicines-10-00212-g004" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f005"><label>Figure 5</label><caption><p>HPLC-LTQ-MS analysis for 2-N&#x02019;-acyl substituted KSM analogs generated using KasH. (<bold>A</bold>) EIC spectra of (i) KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 380.13 [M+H], (ii) Ac-KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 422.19 [M+H], (iii) isovaleryl-KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 464.10 [M+H], (iv) &#x003b2;-hydroxybutyryl-KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 466.24 [M+H], (v) acetoacetyl-KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 464.35 [M+H], (vi) propionyl-KSM at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 436.05 [M+H]. (<bold>B</bold>) Chemical structures of 2-N&#x02019;-acyl substituted KSM analogs with calculated <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M+H].</p></caption><graphic xlink:href="biomedicines-10-00212-g005" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f006"><label>Figure 6</label><caption><p>Crystal structures of KasQ in complex with UDP or UDP-Glc. (<bold>A</bold>) KasQ&#x02013;WT structure. Monomer 1 is displayed in rainbow colors (N-terminal blue/C-terminal domain in red) and monomer 2 is displayed in gray. The missing residues 40&#x02013;45 and 184&#x02013;190 are designated by dashed lines. (<bold>B</bold>) Superimposition of the KasQ&#x02013;UDP monomer (pale cyan) with the KasQ&#x02013;UDP-Glc monomer (cyan) gives an RMSD of 0.29 &#x000c5;. UDP and UDP-GlcNAc are displayed as yellow and pink sticks, respectively. (<bold>C</bold>) The UDP model fits well into its 2F<sub>o</sub>-F<sub>c</sub> electron density map (contoured at 1 &#x003c3;). (<bold>D</bold>) The UDP-Glc model fits well in its 2F<sub>o</sub>-F<sub>c</sub> electron density map (contoured at 1 &#x003c3;).</p></caption><graphic xlink:href="biomedicines-10-00212-g006" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f007"><label>Figure 7</label><caption><p>Sequence and structural comparison of KasQ with reported UDP-GlcNAc 2-epimerases. (<bold>A</bold>) Superimposition of KasQ&#x02013;UDP-Glc monomer (cyan) with UDP-GlcNAc 2-epimerases of <italic toggle="yes">E. coli</italic> bound with UDP-ManNAc colored blue (PDB entry 1vgv, crystal structure modeled with UDP-ManNAc, mistakenly named UDP-GlcNAc) gives an RMSD of 1.0 &#x000c5;. UDP-Glc and UDP-GlcNAc are colored as pink and blue sticks, respectively. (<bold>B</bold>) Sequence logo of sugar binding-site residues amid KasQ homologs. (<bold>C</bold>) The active site of KasQ&#x02013;UDP-Glc superimposed with that of <italic toggle="yes">E. coli</italic> bound with UDP-ManNAc. (<bold>D</bold>) Superimposition of the KasQ&#x02013;UDP monomer (cyan) with the <italic toggle="yes">E. coli</italic> counterpart bound with UDP (PDB entry 16fd) gives an RMSD of 2.2 &#x000c5;. (<bold>E</bold>) Sequence logo of UDP binding sites amid KasQ homologs. (<bold>F</bold>) Active sites of KasQ&#x02013;UDP superimposed with the <italic toggle="yes">E. coli</italic> counterpart bound with UDP.</p></caption><graphic xlink:href="biomedicines-10-00212-g007" position="float"/></fig><fig position="float" id="biomedicines-10-00212-f008"><label>Figure 8</label><caption><p>Disc diffusion and in vivo isotope incorporation assay. (<bold>A</bold>) Disc diffusion assay shows the zone of inhibition (ZOI) determining the optimal course of kasugamycin production against <italic toggle="yes">E. coli</italic>. (<bold>B</bold>) Isotope incorporation analysis: (i) KSM isolated from the producing strain fed without isotopes, (ii) KSM isolated from the producing strain fed with <sup>13</sup>C1-glucose, (iii) KSM isolated from the producing strain fed with <sup>13</sup>C1-glucosamine, (iv) KSM isolated from the producing strain fed with <sup>13</sup>C1<sup>15</sup>N2-glucosamine, (v) KSM isolated from the producing strain fed with <sup>15</sup>N-glycine, (vi) KSM isolated from the producing strain fed with <sup>15</sup>N-aspartic acid, and (vii) KSM isolated from the producing strain fed with <sup>15</sup>N-glutamic acid. Increments of <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> are colored in light to dark green. (<bold>C</bold>) Schematic diagram of isotope incorporation in KSM.</p></caption><graphic xlink:href="biomedicines-10-00212-g008" position="float"/></fig><table-wrap position="float" id="biomedicines-10-00212-t001"><object-id pub-id-type="pii">biomedicines-10-00212-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of crystal data-collection statistics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">KasQ&#x02013;WT</th><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">KasQ&#x02013;UDP</th><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">KasQ&#x02013;UDP-Glc</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>PDB code</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">7VYY</td><td colspan="3" align="left" valign="middle" rowspan="1">7VZA</td><td colspan="3" align="left" valign="middle" rowspan="1">7VZ6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Wavelength (&#x000c5;)</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">1.0</td><td colspan="3" align="left" valign="middle" rowspan="1">1.0</td><td colspan="3" align="left" valign="middle" rowspan="1">1.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Space group</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">C2</td><td colspan="3" align="left" valign="middle" rowspan="1">P1</td><td colspan="3" align="left" valign="middle" rowspan="1">P1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Cell dimensions</bold>
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold><italic toggle="yes">a</italic>, <italic toggle="yes">b</italic>, <italic toggle="yes">c</italic> (&#x000c5;)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">112.4</td><td align="left" valign="middle" rowspan="1" colspan="1">106.1</td><td align="left" valign="middle" rowspan="1" colspan="1">94.3</td><td align="left" valign="middle" rowspan="1" colspan="1">81.8</td><td align="left" valign="middle" rowspan="1" colspan="1">104.7</td><td align="left" valign="middle" rowspan="1" colspan="1">106.3</td><td align="left" valign="middle" rowspan="1" colspan="1">82.8</td><td align="left" valign="middle" rowspan="1" colspan="1">104.9</td><td align="left" valign="middle" rowspan="1" colspan="1">106.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold><italic toggle="yes">&#x003b1;</italic>, <italic toggle="yes">&#x003b2;</italic>, <italic toggle="yes">&#x003b3;</italic> (&#x000b0;)</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">90</td><td align="left" valign="middle" rowspan="1" colspan="1">124.9</td><td align="left" valign="middle" rowspan="1" colspan="1">90</td><td align="left" valign="middle" rowspan="1" colspan="1">74.5</td><td align="left" valign="middle" rowspan="1" colspan="1">73.0</td><td align="left" valign="middle" rowspan="1" colspan="1">68.4</td><td align="left" valign="middle" rowspan="1" colspan="1">74.9</td><td align="left" valign="middle" rowspan="1" colspan="1">72.9</td><td align="left" valign="middle" rowspan="1" colspan="1">68.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Resolution (&#x000c5;)</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">25.45&#x02013;2.44 (2.55&#x02013;2.46)</td><td colspan="3" align="left" valign="middle" rowspan="1">19.89&#x02013;2.60 (2.68&#x02013;2.60)</td><td colspan="3" align="left" valign="middle" rowspan="1">21.56&#x02013;2.10 (2.18&#x02013;2.10)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">R</italic>
<sub>merge</sub>
</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">0.031 (0.387)</td><td colspan="3" align="left" valign="middle" rowspan="1">0.023 (0.365)</td><td colspan="3" align="left" valign="middle" rowspan="1">0.035 (0.296)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold><italic toggle="yes">I</italic>/<italic toggle="yes">I</italic></bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">26.6 (2.4)</td><td colspan="3" align="left" valign="middle" rowspan="1">23.8 (1.9)</td><td colspan="3" align="left" valign="middle" rowspan="1">19.7 (2.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Completeness (%)</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">85.9 (86)</td><td colspan="3" align="left" valign="middle" rowspan="1">93.9 (94.1)</td><td colspan="3" align="left" valign="middle" rowspan="1">95.2 (95.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Redundancy</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">3.6 (3.9)</td><td colspan="3" align="left" valign="middle" rowspan="1">2.4 (2.5)</td><td colspan="3" align="left" valign="middle" rowspan="1">2.2 (2.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Refinement</bold>
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Resolution (&#x000c5;)</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">25.45&#x02013;2.44 (2.55&#x02013;2.44)</td><td colspan="3" align="left" valign="middle" rowspan="1">19.9&#x02013;2.58 (2.68&#x02013;2.58)</td><td colspan="3" align="left" valign="middle" rowspan="1">21.5&#x02013;2.09 (2.14&#x02013;2.09)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>No. reflections</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">28,957</td><td colspan="3" align="left" valign="middle" rowspan="1">91,395</td><td colspan="3" align="left" valign="middle" rowspan="1">176,474</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold><italic toggle="yes">R</italic><sub>work</sub>/<italic toggle="yes">R</italic><sub>free</sub></bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">0.22/0.27</td><td colspan="3" align="left" valign="middle" rowspan="1">0.21/0.24</td><td colspan="3" align="left" valign="middle" rowspan="1">0.20/0.22</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>R.m.s deviations</bold>
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td><td colspan="3" align="center" valign="middle" rowspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Bond lengths (&#x000c5;)</bold>
</td><td colspan="3" align="left" valign="middle" rowspan="1">0.66</td><td colspan="3" align="left" valign="middle" rowspan="1">0.66</td><td colspan="3" align="left" valign="middle" rowspan="1">0.70</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bond angles (&#x000b0;)</bold>
</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">0.77</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">0.79</td><td colspan="3" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">0.84</td></tr></tbody></table></table-wrap><table-wrap position="float" id="biomedicines-10-00212-t002"><object-id pub-id-type="pii">biomedicines-10-00212-t002_Table 2</object-id><label>Table 2</label><caption><p>The sequences of primers used in this study to create KasQ mutants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutants</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primers</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Q95A</td><td align="center" valign="middle" rowspan="1" colspan="1">Forward 5&#x02032;-TGGTGTCTCCCGCTACCACGGCGACGTCC-3&#x02032;<break/>Reverse 5&#x02032;-GGACGTCGCCGTGGTAGCGGGAGACACCA-3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Q95E</td><td align="center" valign="middle" rowspan="1" colspan="1">Forward 5&#x02032;-TGTCTCCCTCTACCACGGCGACGTCCA-3&#x02032;<break/>Reverse 5&#x02032;-TGGACGTCGCCGTGGTAGAGGGAGACA-3&#x02032;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">E308A</td><td align="center" valign="middle" rowspan="1" colspan="1">Forward 5&#x02032;-CCTCGGGGCGCGCCGTGCGGTCC-3&#x02032;<break/>Reverse 5&#x02032;-GGACCGCACGGCGCGCCCCGAGG-3&#x02032;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E308Q</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forward 5&#x02032;-CTCGGGGCGCTGCGTGCGGTCCC-3&#x02032;<break/>Reverse 5&#x02032;-GGGACCGCACGCAGCGCCCCGAG-3&#x02032;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="biomedicines-10-00212-t003"><object-id pub-id-type="pii">biomedicines-10-00212-t003_Table 3</object-id><label>Table 3</label><caption><p>The sequences of primers used to construct pMKBAC08-KAS and pWZC07-PrpsJ-kasT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">P303<break/>P304<break/>P115<break/>P116<break/>P117<break/>P118</td><td align="left" valign="middle" rowspan="1" colspan="1">TAACCGTTTAAACTTAATTAAGAAGATCCTTTGATCTTTTCTACGG<break/> AAGCCCTGGATCCAATTCCCCAATGTCAAGCACTT<break/>ATTATTATTCATATGCGCGTCATCGACGGGATGCACCGGCT<break/>ACCTGTGTTCAACCAAGGAATTTCCTGGGTTGAACACCGC <break/>AAGATCAGATCCCCGCGGTGACGTAGTACGAGAT<break/>ACAGCGTCATGACGTGAAGTTCAGCGACCCGT</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P119<break/>P120<break/>P121<break/>P122<break/>P123<break/>P124</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATTATTATTCAATTGCACTACAAGTTCCGCTGGGTGTACCTGAATTT<break/> ATTATTATTTTAATTAAGCTTATTCGCAGCAGTCCTCGATGACGAAGACA<break/>CAGGAAATTCGAGGCGGAATTCGCCGAATCCTT<break/>TGCCTTGTCGTCGTAGGTGTGGAGGCTGTT<break/>TTCGACATCGGCATGATCACCCACGGTCTGCTCT<break/>ATTATTATTAAGCTTAACAACGTGACGGGTTCAGCCAGTTACCGCTTCATGCTT</td></tr></tbody></table></table-wrap><table-wrap position="float" id="biomedicines-10-00212-t004"><object-id pub-id-type="pii">biomedicines-10-00212-t004_Table 4</object-id><label>Table 4</label><caption><p>Thermodynamic parameters of KasQ versus different substrates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">S.No</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">KasQ with</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">K<sub>d</sub> (&#x000b5;M)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;G (kcal mol<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;H (kcal mol<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;S (cal mol<sup>&#x02212;1</sup> K<sup>&#x02212;1</sup>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">AMP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">ADP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">GMP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">GDP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">GTP</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">TTP</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 &#x000b1; 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">174.5 &#x000b1; 20.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.128 &#x000b1; 1.221 </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.612 &#x000b1; 1.221</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">UMP</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 &#x000b1; 0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">123.9 &#x000b1; 70.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;13.19 &#x000b1; 1.245</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.254 &#x000b1; 1.245</td><td align="center" valign="middle" rowspan="1" colspan="1">13.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP <bold>3</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 &#x000b1; 0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">32.2 &#x000b1; 6.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.128 &#x000b1; 0.5523</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.130 &#x000b1; 0.5523</td><td align="center" valign="middle" rowspan="1" colspan="1">6.70</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">UTP</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 &#x000b1; 0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">71.4 &#x000b1; 5.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.645 &#x000b1; 1.340</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.104 &#x000b1; 1.340</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;11.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-GlcNAc <bold>1</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-GlcNAc/Mg<sup>2+</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-GalNAc</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">334.4 &#x000b1; 133. 7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.742 &#x000b1; 1.700</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.418 &#x000b1; 1.700</td><td align="center" valign="middle" rowspan="1" colspan="1">4.44</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-Glc</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 &#x000b1; 0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5 &#x000b1; 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.834 &#x000b1; 0.0375</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3944 &#x000b1; 0.0375</td><td align="center" valign="middle" rowspan="1" colspan="1">21.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">TDP-Glc</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3 &#x000b1; 0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">25.1 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.273 &#x000b1; 0.2773</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.568 &#x000b1; 0.2773</td><td align="center" valign="middle" rowspan="1" colspan="1">5.72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">GDP-Glc</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-Gal</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">273.3 &#x000b1; 54.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.862 &#x000b1; 1.926</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.636 &#x000b1; 1.926</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.95</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-GlcA</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">76.3 &#x000b1; 15.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.61 &#x000b1; 0.5751</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.376 &#x000b1; 0.5751</td><td align="center" valign="middle" rowspan="1" colspan="1">14.2 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">GDP-Man</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">UDP-GlcNH<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">GlcNAc</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">GalNAc</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">GlcNH<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">GlcA</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">GalA</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">D-Glucose</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">D-Mannose</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">D-Galactose</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" rowspan="1" colspan="1">NBD</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AAG <bold>2</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NBD</td></tr></tbody></table><table-wrap-foot><fn><p>NBD: No binding detected.</p></fn></table-wrap-foot></table-wrap></sec></back></article>